Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:fatty acid derivative
go back to main search page
Accession:CHEBI:61697 term browser browse the term
Definition:Any organic molecular entity derived from a fatty acid.
Synonyms:related_synonym: FA derivative;   FA derivatives;   fatty acid derivatives


show annotations for term's descendants           Sort by:
 
(5Z,8Z,11Z,13E)-15-HETE term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Alox15 arachidonate 15-lipoxygenase multiple interactions
increases abundance
increases chemical synthesis
EXP
ISO
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]
ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
[ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
CTD PMID:18984061, PMID:21193584, PMID:23872364 NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions ISO [benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CTD PMID:2849922 NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
JBrowse link
G Egf epidermal growth factor multiple interactions
increases chemical synthesis
ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]
EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid
CTD PMID:15613483 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Ephx2 epoxide hydrolase 2 increases activity ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of EPHX2 protein CTD PMID:25600587 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] CTD PMID:15613483 NCBI chr 4:15,435,460...15,505,377
Ensembl chr 4:15,433,295...15,505,362
JBrowse link
G Il1b interleukin 1 beta increases secretion
multiple interactions
ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein
IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
CTD PMID:23355332 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Kcna5 potassium voltage-gated channel subfamily A member 5 multiple interactions
affects activity
EXP [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein
CTD PMID:18984061 NCBI chr 4:159,077,195...159,079,003
Ensembl chr 4:159,077,195...159,079,003
JBrowse link
G Kcnb1 potassium voltage-gated channel subfamily B member 1 affects activity EXP 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNB1 protein CTD PMID:18984061 NCBI chr 3:163,850,785...163,935,610
Ensembl chr 3:163,850,785...163,935,617
JBrowse link
G Kcnc4 potassium voltage-gated channel subfamily C member 4 affects activity EXP 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNC4 protein CTD PMID:18984061 NCBI chr 2:210,220,908...210,241,447
Ensembl chr 2:210,220,908...210,241,455
JBrowse link
G Krt1 keratin 1 multiple interactions ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] CTD PMID:12069687 NCBI chr 7:143,448,318...143,453,544
Ensembl chr 7:143,448,318...143,453,544
JBrowse link
G Lyz2 lysozyme 2 increases secretion
multiple interactions
ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein
[parthenolide co-treated with artemisinine co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinine inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
CTD PMID:23355332 NCBI chr 7:60,335,968...60,341,264
Ensembl chr 7:60,335,969...60,341,264
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK1 protein CTD PMID:25600587 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK3 protein CTD PMID:25600587 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 increases activity
affects localization
multiple interactions
ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein
artemisinine inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein]
CTD PMID:23355332, PMID:25600587 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
CTD PMID:15451026, PMID:23355332 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nppa natriuretic peptide A increases expression ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPA mRNA CTD PMID:25600587 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Nppb natriuretic peptide B increases expression ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPB mRNA CTD PMID:25600587 NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid binds to and results in increased activity of PPARD protein CTD PMID:12069687 NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
JBrowse link
G Prkca protein kinase C, alpha multiple interactions
increases activity
affects localization
ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein]
calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein]
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein
CTD PMID:15451026, PMID:15613483 NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit increases activity
multiple interactions
affects localization
ISO 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein
artemisinine inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein]
CTD PMID:23355332, PMID:25600587 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases secretion
ISO IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein
CTD PMID:23355332 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 increases glucuronidation ISO UGT1A1 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CTD PMID:15231852 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a2 UDP glucuronosyltransferase 1 family, polypeptide A2 increases glucuronidation ISO UGT1A3 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CTD PMID:15231852 NCBI chr 9:95,285,592...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a5 UDP glucuronosyltransferase family 1 member A5 increases glucuronidation ISO UGT1A4 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CTD PMID:15231852 NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 increases glucuronidation ISO UGT1A9 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CTD PMID:15231852 NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases glucuronidation ISO UGT2B7 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CTD PMID:15231852 NCBI chr14:22,597,103...22,619,968 JBrowse link
11-dehydro-thromboxane B2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Apoe apolipoprotein E multiple interactions ISO APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] CTD PMID:20530721 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
JBrowse link
G Ldlr low density lipoprotein receptor multiple interactions ISO Aspirin inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] CTD PMID:20530721 NCBI chr 8:22,750,425...22,773,305
Ensembl chr 8:22,750,336...22,774,903
JBrowse link
12(S)-HPETE term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Gpx1 glutathione peroxidase 1 increases response to substance ISO GPX1 protein results in increased susceptibility to 12-HPETE CTD PMID:11115402 NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
JBrowse link
G Gpx4 glutathione peroxidase 4 increases chemical synthesis ISO GPX4 protein results in increased chemical synthesis of 12-HPETE CTD PMID:11115402 NCBI chr 7:12,516,357...12,519,154
Ensembl chr 7:12,516,352...12,519,154
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO 12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein] CTD PMID:12538810 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
13,14-dihydro-15-keto-PGF2alpha term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgr1 prostaglandin reductase 1 increases abundance
multiple interactions
ISO PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha
[PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha
CTD PMID:25619643 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
13,14-dihydro-15-ketoprostaglandin D2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO 13,14-dihydro-15-ketoprostaglandin D2 results in increased expression of CXCL2 protein
13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of CXCL2 mRNA]
CTD PMID:21094227, PMID:21735453 NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
JBrowse link
G Gata3 GATA binding protein 3 multiple interactions ISO 13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of GATA3 mRNA] CTD PMID:21735453 NCBI chr17:72,419,752...72,452,043
Ensembl chr17:72,429,618...72,450,681
JBrowse link
G Il4 interleukin 4 multiple interactions ISO 13,14-dihydro-15-ketoprostaglandin D2 promotes the reaction [Flutamide results in increased expression of IL4 protein] CTD PMID:21735453 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO 13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR protein; 13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] CTD PMID:9579725 NCBI chr15:19,195,606...19,196,508 JBrowse link
G Ptgdr2 prostaglandin D2 receptor 2 multiple interactions ISO
EXP
13,14-dihydro-15-ketoprostaglandin D2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]
13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [13,14-dihydro-15-ketoprostaglandin D2 binds to and results in increased activity of PTGDR2 protein]
CTD PMID:12721327, PMID:15528449, PMID:16256979 NCBI chr 1:226,976,455...226,995,641
Ensembl chr 1:226,993,250...226,994,849
JBrowse link
13,14-dihydro-15-oxo-prostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgr1 prostaglandin reductase 1 increases abundance
multiple interactions
ISO PTGR1 protein results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2
[PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2
CTD PMID:25619643 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
13,14-dihydro-15-oxoprostaglandin E1 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgr1 prostaglandin reductase 1 increases abundance
multiple interactions
ISO PTGR1 protein results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1
[PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E] which results in increased abundance of 13,14-dihydro-15-ketoprostaglandin E1
CTD PMID:25619643 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
13,14-dihydro-Delta(12)-prostaglandin J2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bdnf brain-derived neurotrophic factor increases expression
multiple interactions
EXP 9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA
Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of BDNF mRNA]
CTD PMID:22982731 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Gdnf glial cell derived neurotrophic factor multiple interactions
increases expression
EXP Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA]; NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] CTD PMID:22982731 NCBI chr 2:56,884,181...56,912,964
Ensembl chr 2:56,887,987...56,910,238
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions EXP NFE2L2 protein affects the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of GDNF mRNA] CTD PMID:22982731 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Ngf nerve growth factor multiple interactions
increases expression
EXP Dactinomycin inhibits the reaction [9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin D2 analog results in increased expression of NGF mRNA] CTD PMID:22982731 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
JBrowse link
14,15-EET term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme decreases activity EXP 14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein CTD PMID:27428043 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Ace2 angiotensin I converting enzyme 2 multiple interactions ISO 14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein] CTD PMID:27428043 NCBI chr  X:32,050,734...32,095,860
Ensembl chr  X:32,049,931...32,096,016
JBrowse link
G Agt angiotensinogen decreases expression
multiple interactions
increases cleavage
EXP
ISO
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form
[14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7)
14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form]
CTD PMID:27428043 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation ISO 14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein CTD PMID:16286479 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Cyp2c79 cytochrome P450, family 2, subfamily c, polypeptide 79 increases chemical synthesis ISO CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid CTD PMID:12675279 NCBI chr 1:147,236,480...147,307,988 JBrowse link
G Ephx2 epoxide hydrolase 2 multiple interactions
increases abundance
ISO [Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid
EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid
CTD PMID:19896470, PMID:22680237, PMID:24472606 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
G Fgf2 fibroblast growth factor 2 increases expression ISO 14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein CTD PMID:16286479 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation ISO 14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein CTD PMID:19464254 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 increases phosphorylation ISO 14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein CTD PMID:19464254 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 increases phosphorylation ISO 14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein CTD PMID:16286479 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases secretion
multiple interactions
ISO TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid
12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid]
CTD PMID:28694203 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
15-dehydro-prostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases chemical synthesis ISO HPGD protein results in increased chemical synthesis of 15-ketoprostaglandin E2 CTD PMID:20448048 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Ptgr1 prostaglandin reductase 1 multiple interactions
increases metabolic processing
increases reduction
EXP
ISO
15-ketoprostaglandin E2 inhibits the reaction [PTGR1 protein results in increased reduction of 10-nitro-oleic acid analog]; Dithionitrobenzoic Acid inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2]; Indomethacin inhibits the reaction [PTGR1 protein results in increased reduction of 15-ketoprostaglandin E2]
[PTGR1 protein results in increased metabolism of 15-ketoprostaglandin E2] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin E2
CTD PMID:23878198, PMID:25619643 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
15-deoxy-Delta(12,14)-prostaglandin J2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc1 ATP binding cassette subfamily C member 1 multiple interactions
affects export
affects glutathionylation
increases transport
ISO [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]
ABCC1 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog
ABCC1 protein affects the glutathionylation of 15-deoxy-delta(12,14)-prostaglandin J2
CTD PMID:14979731, PMID:21728338 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 affects export ISO ABCC3 protein affects the export of 15-deoxy-delta(12,14)-prostaglandin J2 analog CTD PMID:14979731 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
JBrowse link
G Agt angiotensinogen multiple interactions EXP 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] CTD PMID:18278065 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 multiple interactions ISO [Medroxyprogesterone Acetate inhibits the reaction [[AKR1C3 protein results in increased metabolism of Prostaglandin D2] which results in increased abundance of Dinoprost]] which results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2 CTD PMID:19997560 NCBI chr17:69,761,126...69,778,021
Ensembl chr17:69,761,118...69,778,021
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of AKT1 protein CTD PMID:16611854 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bglap bone gamma-carboxyglutamate protein decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BGLAP mRNA CTD PMID:12021203 NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC2 protein CTD PMID:15498850 NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of BIRC3 protein CTD PMID:15498850 NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions
increases cleavage
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of CASP3 protein
[delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of CASP3 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of CASP3 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP3 protein
CTD PMID:11785780, PMID:15498850, PMID:16299251, PMID:23973622 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP8 protein CTD PMID:15498850 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Casp9 caspase 9 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of and results in increased activity of CASP9 protein CTD PMID:15498850 NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
JBrowse link
G Cat catalase multiple interactions ISO CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]] CTD PMID:12847270 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein] CTD PMID:15187150 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccl5 C-C motif chemokine ligand 5 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA] CTD PMID:23688403 NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] CTD PMID:19429239 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccna2 cyclin A2 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNA2 protein CTD PMID:15729575 NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
JBrowse link
G Ccnb1 cyclin B1 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNB1 protein CTD PMID:15729575 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCND3 protein CTD PMID:15729575 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Ccne1 cyclin E1 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CCNE1 protein CTD PMID:15729575 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cdk2 cyclin dependent kinase 2 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDK2 protein CTD PMID:15729575 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
decreases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CDKN1A
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1A protein
CTD PMID:15254749, PMID:15729575 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CDKN1B protein CTD PMID:15729575 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha increases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of CEBPA mRNA CTD PMID:12021203 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of CFLAR protein CTD PMID:15498850 NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex multiple interactions ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of CHUK protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased phosphorylation of CHUK protein]
CTD PMID:15498850, PMID:22245093 NCBI chr 1:263,848,829...263,884,354
Ensembl chr 1:263,848,884...263,885,169
JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of COL1A1 mRNA CTD PMID:12021203 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of CSF2 mRNA]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]] CTD PMID:12604364, PMID:14998300 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Ddx58 DEXD/H-box helicase 58 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of DDX58 mRNA] CTD PMID:16303604 NCBI chr 5:56,486,584...56,536,898
Ensembl chr 5:56,500,734...56,536,772
JBrowse link
G Egr1 early growth response 1 multiple interactions EXP 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of and results in increased activity of EGR1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Oxygen deficiency results in increased expression of EGR1 mRNA] CTD PMID:12468449 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions
increases expression
ISO [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Tretinoin] results in increased expression of FABP4 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FABP4 mRNA
CTD PMID:9543393, PMID:12021203, PMID:16573735 NCBI chr 2:93,792,666...93,797,267
Ensembl chr 2:93,792,601...93,797,305
JBrowse link
G Fas Fas cell surface death receptor decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of FAS mRNA CTD PMID:16712844 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]; wortmannin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of FOS mRNA]
CTD PMID:11457450, PMID:11687581 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; [ABCC1 protein results in increased transport of 15-deoxy-delta(12,14)-prostaglandin J2 metabolite] affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; [verlukast binds to and results in decreased activity of ABCC1 protein] inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein
CTD PMID:21728338 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gfap glial fibrillary acidic protein increases expression
decreases expression
multiple interactions
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GFAP
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of GFAP mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in decreased expression of GFAP mRNA]
CTD PMID:15254749, PMID:15994020 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gsta3 glutathione S-transferase alpha 3 increases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTA3 mRNA CTD PMID:14652005 NCBI chr 9:27,357,490...27,417,023
Ensembl chr 9:27,402,381...27,417,023
JBrowse link
G Gstm1 glutathione S-transferase mu 1 multiple interactions ISO GSTM1 protein affects the metabolism of [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with Glutathione] CTD PMID:14979731 NCBI chr 2:210,803,869...210,809,461
Ensembl chr 2:210,803,869...210,809,306
JBrowse link
G Gstp1 glutathione S-transferase pi 1 increases expression
multiple interactions
EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein
Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 mRNA]; Soybean Oil promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GSTP1 protein]
CTD PMID:11600134 NCBI chr 1:219,291,679...219,294,147
Ensembl chr 1:219,291,679...219,294,147
JBrowse link
G Hdac1 histone deacetylase 1 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC1 mRNA CTD PMID:21957481 NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723
JBrowse link
G Hdac2 histone deacetylase 2 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC2 mRNA CTD PMID:21957481 NCBI chr20:43,084,870...43,108,198
Ensembl chr20:43,084,870...43,108,198
JBrowse link
G Hdac3 histone deacetylase 3 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HDAC3 mRNA CTD PMID:21957481 NCBI chr18:31,073,057...31,094,347
Ensembl chr18:31,073,058...31,094,303
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha affects stability
multiple interactions
increases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 affects the stability of HIF1A protein
Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Buthionine Sulfoximine promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Dithiothreitol inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HIF1A protein]
CTD PMID:17658243 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein; [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; zinc protoporphyrin inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron]
ochratoxin A inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 protein
CTD PMID:11078701, PMID:15618017, PMID:15994020, PMID:19136476 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Hsf1 heat shock transcription factor 1 multiple interactions ISO HSF1 protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA] CTD PMID:15618017 NCBI chr 7:117,538,523...117,565,478
Ensembl chr 7:117,538,523...117,565,478
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of HSPB1 protein CTD PMID:16299251 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
JBrowse link
G Ifng interferon gamma multiple interactions
decreases expression
decreases secretion
ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased abundance of Nitric Oxide]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased secretion of IFNG protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IFNG protein
CTD PMID:12847270, PMID:16844232, PMID:19888466 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA] CTD PMID:14998300 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1b interleukin 1 beta multiple interactions
decreases expression
decreases activity
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in decreased abundance of Prostaglandins]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased abundance of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of IL1A mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein]; Dexamethasone promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of CSF2 mRNA]]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1B protein
[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with IL1B protein] results in decreased secretion of IL1B protein
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of IL1B protein
CTD PMID:11457450, PMID:12604364, PMID:14998300, PMID:15751073, PMID:16461118 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il1rn interleukin 1 receptor antagonist decreases expression EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of IL1RN mRNA CTD PMID:15751073 NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
JBrowse link
G Il4 interleukin 4 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CCL5 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of CXCL8 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; 4-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-1-(4-(2H-tetrazol-5-yl)butyl)piperidine inhibits the reaction [Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]]; [Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2; amorolfine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; butenafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Itraconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Ketoconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; luliconazole inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2]; Terbinafine inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in decreased secretion of 15-deoxy-delta(12,14)-prostaglandin J2] CTD PMID:23688403 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il6 interleukin 6 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] CTD PMID:12604364, PMID:12847270 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ins2 insulin 2 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified inhibits the reaction [INS protein results in increased secretion of Glucose]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of INS mRNA] CTD PMID:14625208 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Irf1 interferon regulatory factor 1 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of IRF1 mRNA] CTD PMID:12847270 NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
JBrowse link
G Jak2 Janus kinase 2 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of and results in increased activity of JAK2 protein]] CTD PMID:12847270 NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [FOS protein binds to JUN protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [IL1B protein affects the localization of JUN protein] CTD PMID:11457450 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Klf6 Kruppel-like factor 6 multiple interactions ISO [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] CTD PMID:16611854 NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
JBrowse link
G Lep leptin multiple interactions
increases secretion
ISO [Dexamethasone co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased secretion of LEP protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased secretion of LEP protein
CTD PMID:11092516 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Lif LIF, interleukin 6 family cytokine multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]] CTD PMID:19922793 NCBI chr14:84,482,652...84,500,574
Ensembl chr14:84,482,674...84,500,642
JBrowse link
G Lpl lipoprotein lipase increases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of LPL mRNA CTD PMID:12021203 NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
multiple interactions
increases phosphorylation
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK1 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK1 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK1 protein]
CTD PMID:11687581, PMID:12083801, PMID:16611854, PMID:19888466 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions
increases phosphorylation
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of MAPK3 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]; U 0126 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of and results in increased activity of MAPK3 protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MAPK3 protein; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of MAPK3 protein]
CTD PMID:11687581, PMID:12083801, PMID:16611854, PMID:19888466 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Med1 mediator complex subunit 1 multiple interactions ISO MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein] CTD PMID:16324150 NCBI chr10:86,101,560...86,145,271
Ensembl chr10:86,103,600...86,144,880
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions
increases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein; [[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased expression of MMP1 mRNA; [[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein; Acetylcysteine inhibits the reaction [[[[15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of HMOX1 protein] which results in increased abundance of Iron] which results in increased abundance of Reactive Oxygen Species] which results in increased expression of MMP1 protein]; Cycloheximide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Dactinomycin inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]; Deferoxamine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 protein]; HMOX1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and results in increased activity of MMP1 protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA] CTD PMID:19136476 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of MMP9 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of MMP9 mRNA] CTD PMID:19997048 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of MTOR protein CTD PMID:16611854 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Nes nestin increases expression EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NES protein CTD PMID:15212945 NCBI chr 2:187,343,109...187,352,972
Ensembl chr 2:187,344,056...187,352,969
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased activity of NFE2L2 protein; 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]; ABCC1 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [NFE2L2 protein results in increased expression of GCLC protein]]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of NFE2L2 protein]; NFE2L2 protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of HMOX1 mRNA]; NFE2L2 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of MMP1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of and affects the localization of NFE2L2 protein; manganese chloride inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of NFE2L2 protein]
CTD PMID:19136476, PMID:21728338, PMID:22245093 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
decreases localization
ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased localization of NFKB1 protein
CTD PMID:11457450, PMID:16299251 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
decreases phosphorylation
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased degradation of NFKBIA protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in increased degradation of NFKBIA protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of NFKBIA protein
CTD PMID:15498850, PMID:22245093, PMID:23688403 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions
decreases activity
decreases expression
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of NOS2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS2 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[IFNG protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased expression of NOS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of NOS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of NOS2 mRNA]
CTD PMID:11457450, PMID:11890746, PMID:12847270, PMID:15684285, PMID:15994020, PMID:16461118, PMID:19997048 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Nos3 nitric oxide synthase 3 decreases activity EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of NOS3 protein CTD PMID:11890746 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Nr3c1 nuclear receptor subfamily 3, group C, member 1 affects activity
multiple interactions
ISO 15-deoxy-delta(12,14)-prostaglandin J2 affects the activity of NR3C1 protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Dexamethasone binds to NR3C1 protein] which results in decreased expression of CCL2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Dexamethasone binds to NR3C1 protein]
CTD PMID:15187150 NCBI chr18:31,728,373...32,704,022
Ensembl chr18:31,728,373...31,749,647
JBrowse link
G Park7 Parkinsonism associated deglycase multiple interactions EXP 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride results in decreased expression of PARK7 protein] CTD PMID:22245093 NCBI chr 5:167,982,438...168,004,724
Ensembl chr 5:167,982,439...168,004,724
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 results in increased cleavage of PARP1 protein
[delta(12)-prostaglandin J(2) co-treated with 9-deoxy-delta-9-prostaglandin D2 co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in increased cleavage of PARP1 protein
CTD PMID:15498850, PMID:23973622 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 increases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PCK1 mRNA CTD PMID:9518257 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARA protein CTD PMID:9013583 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta increases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARD protein CTD PMID:17341418 NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma affects expression
decreases response to substance
increases expression
increases activity
multiple interactions
decreases expression
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 affects the expression of PPARG
PPARG protein mutant form results in decreased susceptibility to 15-deoxy-delta(12,14)-prostaglandin J2
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG mRNA; 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PPARG protein
15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in decreased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ochratoxin A results in increased expression of PPARG mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [PPARG protein affects the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]]; MED1 protein promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]
15-deoxy-delta(12,14)-prostaglandin J2 affects the localization of and results in increased expression of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in decreased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased localization of and results in increased activity of PPARG protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [deoxynivalenol results in increased expression of PPARG protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Fatty Acids, Nonesterified results in decreased expression of PPARG mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in decreased expression of PPARG mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; MG 262 promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of PPARG protein]; PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PPARG protein
CTD PMID:9013583, PMID:10662598, PMID:11030710, PMID:12065695, PMID:12604364, PMID:12839938, PMID:12847270, PMID:14625208, PMID:14979731, PMID:14998300, PMID:15212945, PMID:15254749, PMID:15322177, PMID:15491415, PMID:15707588, PMID:15729575, PMID:15866424, PMID:15994020, PMID:16324150, PMID:16499875, PMID:17341418, PMID:18278065, PMID:18485432, PMID:19922793, PMID:23943857, PMID:26172262, PMID:30138673 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Pten phosphatase and tensin homolog multiple interactions ISO [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in increased expression of PTEN protein CTD PMID:16611854 NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
JBrowse link
G Ptgdr prostaglandin D2 receptor multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR protein; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR protein] CTD PMID:9579725 NCBI chr15:19,195,606...19,196,508 JBrowse link
G Ptgdr2 prostaglandin D2 receptor 2 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein; ramatroban inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 binds to and results in increased activity of PTGDR2 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Prostaglandin D2 binds to PTGDR2 protein]
CTD PMID:12721327, PMID:16256979 NCBI chr 1:226,976,455...226,995,641
Ensembl chr 1:226,993,250...226,994,849
JBrowse link
G Ptgs1 prostaglandin-endoperoxide synthase 1 multiple interactions ISO PTGS1 protein promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased abundance of 15-deoxy-delta(12,14)-prostaglandin J2] CTD PMID:17439952 NCBI chr 3:15,560,685...15,582,339
Ensembl chr 3:15,560,712...15,582,344
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
decreases expression
increases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased expression of PTGS2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of and results in decreased expression of PTGS2 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of PTGS2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of PTGS2
CTD PMID:11457450, PMID:12604364, PMID:15254749, PMID:19997048 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptpn11 protein tyrosine phosphatase, non-receptor type 11 increases phosphorylation EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in increased phosphorylation of PTPN11 protein CTD PMID:12584205 NCBI chr12:40,895,515...40,955,999
Ensembl chr12:40,895,515...40,955,999
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased activity of and results in decreased phosphorylation of RAF1 protein CTD PMID:12083801 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Rarb retinoic acid receptor, beta multiple interactions
increases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [ciglitazone promotes the reaction [SR 11237 results in increased expression of RARB protein]]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RARB
CTD PMID:12839938, PMID:15254749 NCBI chr15:9,915,223...10,262,599
Ensembl chr15:10,120,206...10,262,599
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased phosphorylation of and results in decreased expression of RB1 protein CTD PMID:15729575 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases activity
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein affects the localization of RELA protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL1B protein results in increased activity of [RELA protein binds to NFKB1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased activity of RELA protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased activity of RELA protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [manganese chloride affects the localization of RELA protein]
CTD PMID:11457450, PMID:15498850, PMID:20174873, PMID:22245093 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rps6ka1 ribosomal protein S6 kinase A1 multiple interactions ISO [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of RPS6KA1 protein CTD PMID:16611854 NCBI chr 5:152,078,217...152,122,684
Ensembl chr 5:152,078,220...152,122,684
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of and results in decreased activity of RPS6KB1 protein; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased phosphorylation of KLF6 protein] CTD PMID:16611854 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of RUNX2 mRNA CTD PMID:12021203 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Rxra retinoid X receptor alpha increases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of RXRA CTD PMID:15254749 NCBI chr 3:6,272,560...6,295,354
Ensembl chr 3:6,211,789...6,295,908
JBrowse link
G Serpine1 serpin family E member 1 multiple interactions EXP 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of and results in increased secretion of SERPINE1 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of SERPINE1 mRNA]] CTD PMID:18278065 NCBI chr12:22,641,104...22,651,482
Ensembl chr12:22,641,104...22,651,482
JBrowse link
G Smad2 SMAD family member 2 multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]] CTD PMID:19429239 NCBI chr18:72,550,107...72,612,078
Ensembl chr18:72,550,219...72,612,078
JBrowse link
G Socs1 suppressor of cytokine signaling 1 increases expression EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS1 mRNA CTD PMID:12584205 NCBI chr10:4,956,795...4,958,472
Ensembl chr10:4,957,326...4,958,461
JBrowse link
G Socs3 suppressor of cytokine signaling 3 increases expression EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of SOCS3 mRNA CTD PMID:12584205 NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
JBrowse link
G Spp1 secreted phosphoprotein 1 decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of SPP1 mRNA CTD PMID:12021203 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901
JBrowse link
G Stat1 signal transducer and activator of transcription 1 multiple interactions ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased activity of and results in increased localization of [STAT1 protein binds to STAT1 protein]]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [peroxyvanadate results in increased phosphorylation of STAT1 protein]; Acetylcysteine inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; CAT protein inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Glutathione inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; Hydrogen Peroxide promotes the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]; peroxyvanadate inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]]
CTD PMID:12584205, PMID:12847270 NCBI chr 9:54,287,540...54,327,958
Ensembl chr 9:54,287,541...54,484,533
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased expression of STAT3 protein]]; T 0070907 inhibits the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [LIF protein results in increased phosphorylation of STAT3 protein]]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of STAT3 protein]
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [IL6 protein results in increased phosphorylation of STAT3 protein]
CTD PMID:12584205, PMID:12847270, PMID:19922793 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tbxa2r thromboxane A2 receptor multiple interactions
decreases expression
ISO PPARG protein affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TBXA2R mRNA alternative form] CTD PMID:16499875 NCBI chr 7:11,253,153...11,259,233
Ensembl chr 7:11,253,180...11,257,977
JBrowse link
G Tg thyroglobulin multiple interactions
increases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein]
15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TG protein
CTD PMID:11078701 NCBI chr 7:107,467,260...107,652,897
Ensembl chr 7:107,467,260...107,652,899
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions
decreases expression
decreases response to substance
ISO
EXP
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of and results in increased secretion of CCN2 protein]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2 mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]; SMAD2 protein modified form affects the reaction [15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [TGFB1 protein results in increased expression of CCN2]]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TGFB1 mRNA
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [AGT protein results in increased expression of TGFB1 protein]
15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [alitretinoin results in decreased expression of TGFB1 mRNA]; 2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; 2-chloro-5-nitrobenzanilide inhibits the reaction [[alitretinoin co-treated with 15-deoxy-delta(12,14)-prostaglandin J2] results in decreased expression of TGFB1 mRNA]; RPS6KB1 protein inhibits the reaction [[15-deoxy-delta(12,14)-prostaglandin J2 co-treated with alitretinoin] results in decreased expression of TGFB1 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased susceptibility to TGFB1 protein
CTD PMID:16611854, PMID:18278065, PMID:19429239 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Th tyrosine hydroxylase increases expression EXP 15-deoxy-delta(12,14)-prostaglandin J2 results in increased expression of TH protein CTD PMID:15212945 NCBI chr 1:216,073,034...216,080,287
Ensembl chr 1:216,073,031...216,080,287
JBrowse link
G Tlr2 toll-like receptor 2 multiple interactions
decreases expression
ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA]
15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TLR2 mRNA
CTD PMID:20174873 NCBI chr 2:182,840,171...182,846,061
Ensembl chr 2:182,840,727...182,846,061
JBrowse link
G Tnf tumor necrosis factor decreases expression
multiple interactions
ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of TNF protein
15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]
CTD PMID:12604364, PMID:19888466 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tshb thyroid stimulating hormone subunit beta multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 promotes the reaction [TSHB protein results in increased expression of TG protein] CTD PMID:11078701 NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681
JBrowse link
G Tslp thymic stromal lymphopoietin multiple interactions ISO 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP mRNA]; 15-deoxy-delta(12,14)-prostaglandin J2 inhibits the reaction [[Poly I-C co-treated with IL4 protein] results in increased expression of TSLP protein] CTD PMID:23688403 NCBI chr18:25,613,601...25,618,066
Ensembl chr18:25,613,831...25,617,361
JBrowse link
G Vim vimentin decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of VIM CTD PMID:15254749 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Wnt10b Wnt family member 10B decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of WNT10B mRNA CTD PMID:12021203 NCBI chr 7:140,448,284...140,466,159
Ensembl chr 7:140,448,465...140,454,268
JBrowse link
G Xiap X-linked inhibitor of apoptosis decreases expression ISO 15-deoxy-delta(12,14)-prostaglandin J2 results in decreased expression of XIAP protein CTD PMID:15498850, PMID:16299251 NCBI chr  X:128,409,425...128,455,786
Ensembl chr  X:128,409,472...128,453,000
JBrowse link
15-oxoprostaglandin F2alpha term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptgr1 prostaglandin reductase 1 increases metabolic processing
multiple interactions
ISO PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha
[PTGR1 protein results in increased metabolism of 15-ketoprostaglandin F2alpha] which results in increased abundance of 15-keto-13,14-dihydroprostaglandin F2alpha
CTD PMID:25619643 NCBI chr 5:76,110,746...76,129,361
Ensembl chr 5:76,110,738...76,129,441
JBrowse link
16,16-dimethylprostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions
ISO 16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein
EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein]
CTD PMID:15578100 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases response to substance
affects localization
ISO BAX results in increased susceptibility to 16,16-Dimethylprostaglandin E2
16,16-Dimethylprostaglandin E2 affects the localization of BAX protein
CTD PMID:15578100 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO EGFR affects the reaction [16,16-Dimethylprostaglandin E2 results in increased phosphorylation of AKT1 protein] CTD PMID:15578100 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Hpgd 15-hydroxyprostaglandin dehydrogenase increases activity ISO 16,16-Dimethylprostaglandin E2 results in increased activity of HPGD protein CTD PMID:14736730 NCBI chr16:37,457,134...37,495,758
Ensembl chr16:37,457,135...37,495,758
JBrowse link
G Mpo myeloperoxidase multiple interactions EXP 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of MPO protein] CTD PMID:11686837, PMID:11855677, PMID:11991626, PMID:18306037 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased activity of NOS2 protein]; 16,16-Dimethylprostaglandin E2 inhibits the reaction [Indomethacin results in increased expression of NOS2 mRNA] CTD PMID:11686837, PMID:11855677, PMID:11991626, PMID:15610444, PMID:18306037 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
ISO
EXP
Flurbiprofen inhibits the reaction [16,16-Dimethylprostaglandin E2 results in increased expression of PTGS2 mRNA]
16,16-Dimethylprostaglandin E2 inhibits the reaction [SC 560 results in increased expression of PTGS2 mRNA]
CTD PMID:9099957, PMID:15610444 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO 16,16-Dimethylprostaglandin E2 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF] CTD PMID:9298541 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
19(S)-HETE term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 affects metabolic processing EXP CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:15205388 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 increases chemical synthesis ISO CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:30259074 NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
JBrowse link
19-HETE term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 affects metabolic processing EXP CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:15205388 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 increases chemical synthesis ISO CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:30259074 NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
JBrowse link
20-HETE term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Clock clock circadian regulator affects abundance ISO CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:22440902 NCBI chr14:34,418,226...34,502,218
Ensembl chr14:34,446,616...34,502,218
JBrowse link
G Cyp4a1 cytochrome P450, family 4, subfamily a, polypeptide 1 multiple interactions
increases chemical synthesis
EXP 20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]]
CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
CTD PMID:11124159, PMID:12388396 NCBI chr 5:134,492,734...134,507,158
Ensembl chr 5:134,492,756...134,507,154
JBrowse link
G Cyp4a2 cytochrome P450, family 4, subfamily a, polypeptide 2 increases expression EXP 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of CYP4A2 mRNA CTD PMID:22442195 NCBI chr 5:134,196,910...134,207,888
Ensembl chr 5:134,196,912...134,207,863
JBrowse link
G Cyp4f18 cytochrome P450, family 4, subfamily f, polypeptide 18 increases chemical synthesis ISO CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:30259074 NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
JBrowse link
G Nfatc4 nuclear factor of activated T-cells 4 multiple interactions
increases localization
ISO
EXP
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein] CTD PMID:16055480 NCBI chr15:34,493,163...34,502,238
Ensembl chr15:34,493,138...34,504,326
JBrowse link
G Pomc proopiomelanocortin multiple interactions
increases abundance
EXP N-hydroxy-N'-(4-butyl-2-methylphenyl)formamidine inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid]
POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid
CTD PMID:18067589, PMID:19458537 NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
JBrowse link
G Ugt1a1 UDP glucuronosyltransferase family 1 member A1 increases glucuronidation ISO UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:15231852 NCBI chr 9:95,295,701...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt1a5 UDP glucuronosyltransferase family 1 member A5 increases glucuronidation ISO UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:15231852 NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822
JBrowse link
G Ugt2b7 UDP glucuronosyltransferase family 2 member B7 increases glucuronidation ISO UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid CTD PMID:15231852 NCBI chr14:22,597,103...22,619,968 JBrowse link
5,6-EET term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ephx2 epoxide hydrolase 2 increases abundance ISO EPHX2 gene mutant form results in increased abundance of 5,6-epoxy-8,11,14-eicosatrienoic acid CTD PMID:19896470 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
6-oxoprostaglandin F1alpha term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen increases abundance
multiple interactions
EXP AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha
Dexamethasone inhibits the reaction [AGT protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha]
CTD PMID:4030047 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Alox15 arachidonate 15-lipoxygenase multiple interactions ISO [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha CTD PMID:21193584 NCBI chr10:56,953,692...56,962,145
Ensembl chr10:56,953,691...56,962,161
JBrowse link
G Apoe apolipoprotein E increases abundance
multiple interactions
ISO APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha
nimesulide inhibits the reaction [APOE results in increased abundance of 6-Ketoprostaglandin F1 alpha]
CTD PMID:14966570 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
JBrowse link
G Avp arginine vasopressin increases abundance
multiple interactions
EXP AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha
Dexamethasone inhibits the reaction [AVP protein results in increased abundance of 6-Ketoprostaglandin F1 alpha]
CTD PMID:4030047 NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
JBrowse link
G Bdkrb2 bradykinin receptor B2 affects abundance
multiple interactions
ISO
EXP
BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha
[kallidin, des-Arg(10)- binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; [KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha
PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha]
CTD PMID:16514058, PMID:29775649 NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
JBrowse link
G Calca calcitonin-related polypeptide alpha decreases abundance
increases abundance
ISO
EXP
CALCA protein alternative form results in decreased abundance of 6-Ketoprostaglandin F1 alpha
CALCA protein results in increased abundance of 6-Ketoprostaglandin F1 alpha
CTD PMID:12024109 NCBI chr 1:184,184,018...184,188,922
Ensembl chr 1:184,184,020...184,188,911
JBrowse link
G Klkb1 kallikrein B1 multiple interactions
increases abundance
ISO 7-Ala-angiotensin (1-7) inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha]; nimesulide inhibits the reaction [KLKB1 gene mutant form results in increased abundance of 6-Ketoprostaglandin F1 alpha] CTD PMID:25339356 NCBI chr16:50,151,127...50,175,407
Ensembl chr16:50,152,008...50,175,458
JBrowse link
G Kng2 kininogen 2 increases abundance
multiple interactions
EXP KNG1 protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha
[KNG1 protein modified form binds to and results in increased activity of BDKRB2 protein] which results in increased secretion of 6-Ketoprostaglandin F1 alpha; Dexamethasone inhibits the reaction [KNG1 protein alternative form results in increased abundance of 6-Ketoprostaglandin F1 alpha]
CTD PMID:4030047, PMID:29775649 NCBI chr11:81,509,185...81,516,759 JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] CTD PMID:16325209 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Ptgis prostaglandin I2 synthase multiple interactions
increases chemical synthesis
EXP [Carnitine results in increased expression of PTGIS mRNA] which results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha
PTGIS protein results in increased chemical synthesis of 6-Ketoprostaglandin F1 alpha
CTD PMID:19491382 NCBI chr 3:163,950,746...163,986,129 JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; NOS2 protein promotes the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha]; PTGS2 gene mutant form inhibits the reaction [[Nanotubes, Carbon co-treated with OVAL protein] results in increased abundance of 6-Ketoprostaglandin F1 alpha]; S-methylisothiopseudouronium inhibits the reaction [[Morphine results in increased expression of PTGS2 protein] which results in increased abundance of 6-Ketoprostaglandin F1 alpha] CTD PMID:16325209, PMID:23642096 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Tnf tumor necrosis factor increases abundance ISO TNF protein results in increased abundance of 6-Ketoprostaglandin F1 alpha CTD PMID:1993070 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
8,9-EET term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ephx1 epoxide hydrolase 1 affects hydrolysis ISO EPHX1 protein affects the hydrolysis of 8,9-epoxyeicosatrienoic acid CTD PMID:28975360 NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
JBrowse link
G Ephx2 epoxide hydrolase 2 increases abundance ISO EPHX2 gene mutant form results in increased abundance of 8,9-epoxyeicosatrienoic acid CTD PMID:19896470 NCBI chr15:42,757,241...42,794,211
Ensembl chr15:42,757,235...42,794,279
JBrowse link
8-epi-prostaglandin E2 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ptger4 prostaglandin E receptor 4 affects response to substance ISO PTGER4 protein affects the susceptibility to 8-isoprostaglandin E2 CTD PMID:22565502 NCBI chr 2:54,951,625...54,966,470
Ensembl chr 2:54,952,821...54,963,448
JBrowse link
8-epi-prostaglandin F2alpha term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Apoe apolipoprotein E multiple interactions ISO [APOE gene mutant form affects the susceptibility to Folic Acid] which results in decreased abundance of 8-epi-prostaglandin F2alpha CTD PMID:17118406 NCBI chr 1:80,612,894...80,616,820
Ensembl chr 1:80,612,895...80,617,057
JBrowse link
G App amyloid beta precursor protein multiple interactions
increases abundance
ISO [Lead co-treated with APP protein modified form] results in increased abundance of 8-epi-prostaglandin F2alpha
APP protein modified form results in increased abundance of 8-epi-prostaglandin F2alpha
CTD PMID:22610977 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases abundance
increases chemical synthesis
ISO
EXP
1-((4-methylsulfonyl)phenyl)-3-trifluoromethyl-5-(4-fluorophenyl)pyrazole inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Ascorbic Acid promotes the reaction [Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]]; Aspirin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Dehydroascorbic Acid inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; Indomethacin inhibits the reaction [IL1B results in increased chemical synthesis of 8-epi-prostaglandin F2alpha]; resveratrol inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]
pyrrolidine dithiocarbamic acid inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]; Rotenone inhibits the reaction [IL1B protein results in increased abundance of 8-epi-prostaglandin F2alpha]
CTD PMID:11530235, PMID:16529823, PMID:19751497 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Pafah2 platelet-activating factor acetylhydrolase 2 affects metabolic processing
multiple interactions
ISO PAFAH2 protein affects the metabolism of 8-epi-prostaglandin F2alpha
PAFAH2 protein affects the reaction [Carbon Tetrachloride results in increased abundance of 8-epi-prostaglandin F2alpha]
CTD PMID:18024956 NCBI chr 5:152,606,850...152,635,956
Ensembl chr 5:152,606,847...152,634,803
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [L 745337 results in decreased activity of PTGS2 protein] which results in decreased chemical synthesis of 8-epi-prostaglandin F2alpha; [lipopolysaccharide, E. coli O26-B6 results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha; [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein] which results in increased chemical synthesis of 8-epi-prostaglandin F2alpha CTD PMID:8621535 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Tbxa2r thromboxane A2 receptor multiple interactions
affects response to substance
ISO 8-epi-prostaglandin F2alpha binds to and results in increased activity of TBXA2R protein
TBXA2R protein affects the susceptibility to 8-epi-prostaglandin F2alpha
CTD PMID:18158556, PMID:22565502 NCBI chr 7:11,253,153...11,259,233
Ensembl chr 7:11,253,180...11,257,977
JBrowse link
AACOCF3 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol] CTD PMID:14613874 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] CTD PMID:18938131 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] CTD PMID:19014389 NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] CTD PMID:29642561 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Ins2 insulin 2 increases secretion
multiple interactions
ISO arachidonyltrifluoromethane results in increased secretion of INS protein
arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein]
CTD PMID:17192482 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
JBrowse link
G Lep leptin multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] CTD PMID:19063610 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein] CTD PMID:15231676 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:15231676 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Nrg1 neuregulin 1 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:15231676 NCBI chr16:62,969,573...64,065,063
Ensembl chr16:63,837,216...64,057,434
JBrowse link
G Pla2g4a phospholipase A2 group IVA multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein]
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA]
CTD PMID:18938131, PMID:19063610, PMID:19162293 NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] CTD PMID:19063610 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]] CTD PMID:18938131, PMID:19063610, PMID:19162293 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G S100a11 S100 calcium binding protein A11 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Oxaliplatin] CTD PMID:25940438 NCBI chr 2:193,863,185...193,868,646
Ensembl chr 2:193,866,951...193,868,502
JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] CTD PMID:19063610 NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] CTD PMID:11264281 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] CTD PMID:11264281 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]
arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]]
CTD PMID:19063610, PMID:19162293 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
acetoacetic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ccl2 C-C motif chemokine ligand 2 increases secretion ISO acetoacetic acid results in increased secretion of CCL2 protein CTD PMID:17665966 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Il6 interleukin 6 increases secretion ISO acetoacetic acid results in increased secretion of IL6 protein CTD PMID:17665966 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Slc13a5 solute carrier family 13 member 5 decreases abundance ISO SLC13A5 protein results in decreased abundance of acetoacetic acid CTD PMID:32634519 NCBI chr10:58,806,581...58,835,549
Ensembl chr10:58,810,058...58,834,538
JBrowse link
acetoacetyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Hsd17b2 hydroxysteroid (17-beta) dehydrogenase 2 affects binding ISO acetoacetyl CoA binds to HSD17B2 protein CTD PMID:25526675 NCBI chr19:50,246,404...50,317,892
Ensembl chr19:50,246,402...50,317,891
JBrowse link
acetone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adh1 alcohol dehydrogenase 1 (class I) multiple interactions ISO [ADH1 protein results in increased oxidation of allyl alcohol] which results in increased abundance of Acetone CTD PMID:11981770 NCBI chr 2:243,550,655...243,562,243
Ensembl chr 2:243,550,627...243,687,857
JBrowse link
G Cat catalase decreases activity ISO
EXP
Acetone results in decreased activity of CAT protein CTD PMID:16169704, PMID:20127315 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Ccnd1 cyclin D1 increases expression ISO Acetone results in increased expression of CCND1 mRNA CTD PMID:12720008 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions EXP Acetone promotes the reaction [Toluene results in increased expression of CYP1A1 protein] CTD PMID:8996725 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions EXP Acetone promotes the reaction [Toluene results in increased expression of CYP1A2 protein] CTD PMID:8996725 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 decreases expression EXP Acetone results in decreased expression of CYP2B1 protein CTD PMID:8267643 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions
increases expression
increases activity
increases metabolic processing
ISO
EXP
[Acetone results in increased activity of CYP2E1 protein] which results in increased oxidation of Benzene; [Acetone results in increased expression of CYP2E1 protein] which results in increased susceptibility to allyl cyanide; Acetone results in increased expression of and results in increased activity of CYP2E1 protein
Acetone results in increased expression of CYP2E1 mRNA; Acetone results in increased expression of CYP2E1 protein
1,2-dichloroethylene inhibits the reaction [Acetone results in increased activity of CYP2E1 protein]; [Acetone co-treated with ciprofibrate] results in increased expression of CYP2E1 protein; [Acetone co-treated with Methylcholanthrene] results in decreased expression of CYP2E1 mRNA; [Acetone co-treated with Methylcholanthrene] results in decreased expression of CYP2E1 protein; [Acetone co-treated with Methylcholanthrene] results in increased activity of CYP2E1 protein; [Acetone co-treated with Methylcholanthrene] results in increased expression of CYP2E1 protein; Acetone promotes the reaction [2-xylene results in increased expression of CYP2E1 protein]; Acetone promotes the reaction [CYP2E1 protein results in increased hydroxylation of 4-nitrophenol]; Acetone promotes the reaction [Toluene results in increased expression of CYP2E1 protein]; Trichloroethylene inhibits the reaction [Acetone results in increased activity of CYP2E1 protein]
CYP2E1 protein results in increased metabolism of Acetone
CTD PMID:1968335, PMID:2241968, PMID:3416296, PMID:3782137, PMID:7587954, PMID:8013281, PMID:8117100, PMID:8267643, PMID:8560479, PMID:8734847, PMID:8996725, PMID:9851676, PMID:11939710, PMID:12919724, PMID:15576447, PMID:15763544, PMID:18990727, PMID:20127315, PMID:22499231 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Fgfr2 fibroblast growth factor receptor 2 increases expression ISO Acetone results in increased expression of FGFR2 mRNA CTD PMID:12720008 NCBI chr 1:200,590,951...200,696,946
Ensembl chr 1:200,590,953...200,696,928
JBrowse link
G Il13 interleukin 13 multiple interactions ISO [Acetone co-treated with Olive Oil] results in increased expression of IL13 mRNA CTD PMID:21252390 NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
JBrowse link
G Il4 interleukin 4 multiple interactions ISO [Acetone co-treated with Olive Oil] results in increased expression of IL4 mRNA CTD PMID:21252390 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il5 interleukin 5 multiple interactions ISO [Acetone co-treated with Olive Oil] results in increased expression of IL5 mRNA CTD PMID:21252390 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
JBrowse link
G Itga5 integrin subunit alpha 5 increases expression ISO Acetone results in increased expression of ITGA5 mRNA CTD PMID:12720008 NCBI chr 7:144,970,444...144,993,652
Ensembl chr 7:144,970,444...144,993,652
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO Acetone results in increased expression of NQO1 mRNA CTD PMID:9496914 NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [Acetone co-treated with Olive Oil] results in increased expression of TNF mRNA CTD PMID:21252390 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Trpm8 transient receptor potential cation channel, subfamily M, member 8 increases response to substance ISO TRPM8 protein results in increased susceptibility to Acetone CTD PMID:17481392 NCBI chr 9:95,393,370...95,484,528
Ensembl chr 9:95,398,237...95,482,890
JBrowse link
acryloyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Echs1 enoyl-CoA hydratase, short chain 1 increases abundance ISO ECHS1 gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 1:212,570,213...212,579,040
Ensembl chr 1:212,570,195...212,579,057
JBrowse link
G Hibch 3-hydroxyisobutyryl-CoA hydrolase increases abundance ISO HIBCH gene mutant form results in increased abundance of acryloyl-coenzyme A CTD PMID:25125611 NCBI chr 9:53,446,185...53,526,727
Ensembl chr 9:53,446,194...53,526,728
JBrowse link
alpha-Sanshool term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adm adrenomedullin increases secretion EXP sanshool analog results in increased secretion of ADM protein CTD PMID:21808981 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
JBrowse link
G Kcnk18 potassium two pore domain channel subfamily K member 18 affects response to substance
decreases activity
multiple interactions
ISO KCNK18 protein affects the susceptibility to sanshool
sanshool results in decreased activity of KCNK18 protein
sanshool inhibits the reaction [KCNK18 protein results in increased transport of Potassium]
CTD PMID:18568022 NCBI chr 1:280,383,579...280,397,784
Ensembl chr 1:280,383,579...280,397,784
JBrowse link
G Kcnk3 potassium two pore domain channel subfamily K member 3 multiple interactions
decreases activity
affects response to substance
ISO sanshool inhibits the reaction [[KCNK3 protein binds to KCNK9 protein] which results in increased transport of Potassium]; sanshool inhibits the reaction [KCNK3 protein results in increased transport of Potassium]; sanshool results in decreased activity of [KCNK3 protein binds to KCNK9 protein]
sanshool results in decreased activity of KCNK3 protein
KCNK3 protein affects the susceptibility to sanshool
CTD PMID:18568022 NCBI chr 6:27,154,274...27,190,209
Ensembl chr 6:27,151,612...27,190,132
JBrowse link
G Kcnk9 potassium two pore domain channel subfamily K member 9 affects response to substance
decreases activity
multiple interactions
ISO KCNK9 protein affects the susceptibility to sanshool
sanshool results in decreased activity of KCNK9 protein
sanshool inhibits the reaction [[KCNK3 protein binds to KCNK9 protein] which results in increased transport of Potassium]; sanshool inhibits the reaction [KCNK9 protein results in increased transport of Potassium]; sanshool results in decreased activity of [KCNK3 protein binds to KCNK9 protein]
CTD PMID:18568022 NCBI chr 7:113,894,918...113,938,397
Ensembl chr 7:113,903,557...113,937,941
JBrowse link
aminoacetone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cat catalase multiple interactions EXP CAT protein results in decreased susceptibility to [aminoacetone co-treated with Copper] CTD PMID:18729331 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Gsr glutathione-disulfide reductase multiple interactions EXP [aminoacetone co-treated with Copper] results in increased expression of GSR mRNA CTD PMID:18729331 NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [aminoacetone co-treated with Copper] results in increased expression of SOD1 mRNA CTD PMID:18729331 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP [aminoacetone co-treated with Copper] results in increased expression of SOD2 mRNA CTD PMID:18729331 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
anandamide term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G App amyloid beta precursor protein decreases response to substance EXP anandamide results in decreased susceptibility to APP protein CTD PMID:22233683 NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
JBrowse link
G Bdkrb1 bradykinin receptor B1 multiple interactions
decreases activity
ISO AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] CTD PMID:19022239 NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
JBrowse link
G Cd36 CD36 molecule increases expression ISO anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein CTD PMID:17360047 NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
JBrowse link
G Cnr1 cannabinoid receptor 1 affects activity
affects binding
increases activity
multiple interactions
ISO
EXP
anandamide affects the activity of CNR1 protein
anandamide binds to CNR1 protein
anandamide results in increased activity of CNR1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; rimonabant inhibits the reaction [anandamide results in increased activity of CNR1]
[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]
CTD PMID:10871313, PMID:11408034, PMID:11891798, PMID:12657697, PMID:14504685, PMID:15453094, PMID:17557913, PMID:19147270 NCBI chr 5:49,307,584...49,333,064
Ensembl chr 5:49,311,030...49,333,056
JBrowse link
G Cnr2 cannabinoid receptor 2 affects activity
affects binding
multiple interactions
ISO
EXP
anandamide affects the activity of CNR2 protein
anandamide binds to CNR2 protein
anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]
CTD PMID:10617657, PMID:10688601, PMID:15453094, PMID:19147270 NCBI chr 5:154,242,010...154,268,126
Ensembl chr 5:154,260,062...154,268,126
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO anandamide results in increased expression of DDIT3 mRNA CTD PMID:21949157 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G F3 coagulation factor III, tissue factor multiple interactions
increases expression
ISO anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
anandamide results in increased expression of F3 protein
CTD PMID:27556861 NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
JBrowse link
G Faah fatty acid amide hydrolase increases degradation
multiple interactions
affects expression
ISO
EXP
FAAH results in increased degradation of anandamide
FAAH protein results in increased degradation of anandamide
[Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]
anandamide affects the expression of FAAH protein
[nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]
CTD PMID:11556820, PMID:16131814, PMID:16886060, PMID:19515121, PMID:20702753, PMID:23761300, PMID:26642910 NCBI chr 5:134,852,899...134,872,095
Ensembl chr 5:134,852,875...134,871,775
JBrowse link
G Faahl fatty-acid amide hydrolase-like increases degradation
affects expression
multiple interactions
ISO FAAH results in increased degradation of anandamide
anandamide affects the expression of FAAH protein
[nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]
CTD PMID:16131814, PMID:16886060, PMID:20702753 NCBI chr 5:134,330,204...134,349,400
Ensembl chr 5:134,331,929...134,348,995
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
EXP anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein]
anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein
CTD PMID:9748483, PMID:15601931, PMID:19515121 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Ifng interferon gamma multiple interactions ISO anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] CTD PMID:12813001 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Igf1 insulin-like growth factor 1 increases expression ISO anandamide results in increased expression of IGF1 protein CTD PMID:17307377 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Il12b interleukin 12B multiple interactions ISO [OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] CTD PMID:15748152 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]
anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein]
CTD PMID:12813001, PMID:15748152, PMID:27556861 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Lep leptin decreases abundance
decreases activity
decreases transport
ISO LEP protein results in decreased abundance of anandamide
LEP protein results in decreased activity of anandamide
LEP protein results in decreased transport of anandamide
CTD PMID:16154199 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] CTD PMID:12657697 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions EXP 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] CTD PMID:12657697 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO
EXP
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
anandamide results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]
CTD PMID:12657697, PMID:19477951, PMID:21179406 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO
EXP
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
anandamide results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]
CTD PMID:12657697, PMID:19477951, PMID:21179406 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mmp1 matrix metallopeptidase 1 increases expression ISO anandamide results in increased expression of MMP1 mRNA CTD PMID:16330497 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp3 matrix metallopeptidase 3 increases expression ISO anandamide results in increased expression of MMP3 mRNA CTD PMID:16330497 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
increases expression
ISO N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] CTD PMID:16330497 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] CTD PMID:11891798, PMID:15748152 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
JBrowse link
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO anandamide binds to and results in increased activity of PPARA protein CTD PMID:17906680 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions
increases expression
increases metabolic processing
EXP
ISO
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide
anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein
PTGS2 results in increased metabolism of anandamide
[nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]
CTD PMID:16330497, PMID:17245358, PMID:20702753 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 increases expression
multiple interactions
ISO anandamide results in increased expression of TIMP1 mRNA
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA]
CTD PMID:16330497 NCBI chr  X:1,364,771...1,369,451
Ensembl chr  X:1,364,786...1,369,384
JBrowse link
G Tnf tumor necrosis factor multiple interactions
increases abundance
EXP
ISO
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein]
TNF protein results in increased abundance of anandamide
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]
CTD PMID:12509806, PMID:12813001, PMID:20626112 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions
increases response to substance
increases activity
affects response to substance
affects binding
ISO
EXP
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]
TRPV1 protein results in increased susceptibility to anandamide
anandamide results in increased activity of TRPV1 protein
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein]
anandamide binds to TRPV1 protein
CTD PMID:11140687, PMID:11278420, PMID:14504685, PMID:15453094, PMID:15601931, PMID:15615864, PMID:17038422, PMID:17913835, PMID:18550765, PMID:21949157 NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO anandamide results in decreased expression of and results in decreased secretion of VEGFA protein CTD PMID:15313899 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
arachidonoyl-CoA term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ppara peroxisome proliferator activated receptor alpha multiple interactions ISO arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein CTD PMID:11139385 NCBI chr 7:126,618,872...126,687,282
Ensembl chr 7:126,619,196...126,681,752
JBrowse link
bucladesine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca1 ATP binding cassette subfamily A member 1 multiple interactions ISO [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA] CTD PMID:20083572, PMID:23227865, PMID:23362264 NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
JBrowse link
G Abcb11 ATP binding cassette subfamily B member 11 multiple interactions EXP Bucladesine inhibits the reaction [tert-Butylhydroperoxide affects the localization of ABCB11 protein] CTD PMID:16452108 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions
increases activity
affects localization
increases expression
EXP
ISO
Bucladesine inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]
Bucladesine results in increased activity of ABCC2 protein
Bucladesine results in increased expression of ABCC2 mRNA; Bucladesine results in increased expression of ABCC2 protein
Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine results in increased activity of and affects the localization of ABCC2 protein; Dactinomycin inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine affects the localization of ABCC2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 mRNA]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ABCC2 protein]; verlukast inhibits the reaction [Bucladesine results in increased activity of ABCC2 protein]
CTD PMID:12029626, PMID:26049102, PMID:29052767 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Ache acetylcholinesterase increases activity
increases expression
EXP Bucladesine results in increased activity of ACHE protein; Bucladesine results in increased activity of ACHE protein alternative form
Bucladesine results in increased expression of ACHE mRNA
CTD PMID:18514641 NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
JBrowse link
G Adamts1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ADAMTS1 mRNA CTD PMID:20823114 NCBI chr11:25,342,119...25,350,938
Ensembl chr11:25,342,126...25,350,974
JBrowse link
G Adm adrenomedullin decreases expression ISO Bucladesine results in decreased expression of ADM mRNA CTD PMID:19253104 NCBI chr 1:175,443,189...175,447,260
Ensembl chr 1:175,445,088...175,447,259
JBrowse link
G Ahr aryl hydrocarbon receptor affects localization
increases activity
multiple interactions
ISO Bucladesine affects the localization of AHR protein
Bucladesine results in increased activity of AHR protein
Bucladesine affects the reaction [Tetrachlorodibenzodioxin results in increased activity of AHR protein]
CTD PMID:15972329 NCBI chr 6:54,963,990...55,001,806
Ensembl chr 6:54,963,990...55,001,464
JBrowse link
G Ahrr aryl-hydrocarbon receptor repressor multiple interactions ISO Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of AHRR mRNA] CTD PMID:21979172 NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329
JBrowse link
G Ak5 adenylate kinase 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of AK5 mRNA CTD PMID:20823114 NCBI chr 2:257,671,772...257,864,385
Ensembl chr 2:257,671,772...257,864,385
JBrowse link
G Akap2 A-kinase anchoring protein 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PALM2AKAP2 mRNA CTD PMID:20823114 NCBI chr 5:74,874,245...74,985,789
Ensembl chr 5:74,874,306...74,982,401
JBrowse link
G Alas1 5'-aminolevulinate synthase 1 multiple interactions ISO [NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA CTD PMID:22859313 NCBI chr 8:114,927,704...114,941,038
Ensembl chr 8:114,927,722...114,940,177
JBrowse link
G Antxr1 ANTXR cell adhesion molecule 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ANTXR1 mRNA CTD PMID:20823114 NCBI chr 4:118,946,267...119,131,202
Ensembl chr 4:118,946,268...119,131,202
JBrowse link
G Anxa2 annexin A2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ANXA2 mRNA CTD PMID:20823114 NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
JBrowse link
G Apoa1 apolipoprotein A1 multiple interactions ISO 27-hydroxycholesterol promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; 27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA; [Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol; Oligomycins inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 protein]; Probucol inhibits the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; TO-901317 promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol] CTD PMID:20083572, PMID:23227865 NCBI chr 8:50,525,091...50,526,875
Ensembl chr 8:50,525,091...50,526,875
JBrowse link
G Ar androgen receptor multiple interactions EXP [Quercetin co-treated with Bucladesine] results in increased expression of AR mRNA CTD PMID:23200735 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Arhgef2 Rho/Rac guanine nucleotide exchange factor 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ARHGEF2 mRNA CTD PMID:20823114 NCBI chr 2:187,964,100...188,022,847
Ensembl chr 2:187,977,008...188,021,377
JBrowse link
G Atf1 activating transcription factor 1 multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of ATF1 protein]] CTD PMID:12164941 NCBI chr 7:141,882,261...141,924,790
Ensembl chr 7:141,882,251...141,924,788
JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression
ISO Bucladesine promotes the reaction [ATF2 protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of ATF2 protein modified form]
Bucladesine results in increased phosphorylation of ATF2 protein
CTD PMID:26049102 NCBI chr 3:60,721,137...60,795,951
Ensembl chr 3:60,721,135...60,795,951
JBrowse link
G Atp11a ATPase phospholipid transporting 11A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP11A mRNA CTD PMID:20823114 NCBI chr16:81,990,340...82,100,222
Ensembl chr16:81,990,340...82,100,222
JBrowse link
G Atp2b1 ATPase plasma membrane Ca2+ transporting 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ATP2B1 mRNA CTD PMID:20823114 NCBI chr 7:41,114,606...41,223,138
Ensembl chr 7:41,114,697...41,220,579
JBrowse link
G Atp6v0c ATPase H+ transporting V0 subunit C multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of ATP6V0C mRNA CTD PMID:20823114 NCBI chr10:13,537,031...13,543,407
Ensembl chr10:13,537,033...13,542,077
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] CTD PMID:16822680 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcat1 branched chain amino acid transaminase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BCAT1 mRNA CTD PMID:20823114 NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
JBrowse link
G Bckdk branched chain ketoacid dehydrogenase kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCKDK mRNA CTD PMID:20823114 NCBI chr 1:199,351,628...199,356,299
Ensembl chr 1:199,351,628...199,356,881
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
decreases expression
ISO adenosine-3',5'-cyclic phosphorothioate inhibits the reaction [Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; Bucladesine inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]
Bucladesine results in decreased expression of BCL2 protein
CTD PMID:10697531, PMID:16822680 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l13 BCL2 like 13 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BCL2L13 mRNA CTD PMID:20823114 NCBI chr 4:153,385,200...153,438,096
Ensembl chr 4:153,385,205...153,436,660
JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions
increases expression
ISO 1-bromopropane inhibits the reaction [Bucladesine results in increased expression of BDNF mRNA]; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:19189864, PMID:29698629 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210
JBrowse link
G Bet1l Bet1 golgi vesicular membrane trafficking protein-like multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BET1L mRNA CTD PMID:20823114 NCBI chr 1:213,602,836...213,606,507
Ensembl chr 1:213,602,850...213,605,643
JBrowse link
G Bicd1 BICD cargo adaptor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of BICD1 mRNA CTD PMID:20823114 NCBI chr 4:184,018,845...184,167,628
Ensembl chr 4:184,019,087...184,165,540
JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions ISO Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] CTD PMID:20522807 NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
JBrowse link
G Bsnd barttin CLCNK type accessory subunit beta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of BSND mRNA CTD PMID:20823114 NCBI chr 5:126,071,849...126,080,647
Ensembl chr 5:126,071,846...126,080,698
JBrowse link
G C1r complement C1r multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of C1R mRNA CTD PMID:20823114 NCBI chr 4:157,126,060...157,136,825
Ensembl chr 4:157,125,998...157,136,829
JBrowse link
G Calm1 calmodulin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CALM1 mRNA CTD PMID:20823114 NCBI chr 6:124,217,241...124,225,292
Ensembl chr 6:124,217,241...124,225,292
JBrowse link
G Calr calreticulin increases stability ISO Bucladesine results in increased stability of CALR protein CTD PMID:9473613 NCBI chr19:25,956,771...25,961,666
Ensembl chr19:25,956,771...25,961,666
JBrowse link
G Capn2 calpain 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAPN2 mRNA CTD PMID:20823114 NCBI chr13:100,878,649...100,928,811
Ensembl chr13:100,878,650...100,928,811
JBrowse link
G Casp3 caspase 3 multiple interactions ISO Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]; Bucladesine promotes the reaction [Hydroxyurea results in increased activity of CASP3 protein] CTD PMID:10697531 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cast calpastatin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CAST mRNA CTD PMID:20823114 NCBI chr 2:1,452,111...1,561,669
Ensembl chr 2:1,452,116...1,561,464
JBrowse link
G Cav2 caveolin 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CAV2 mRNA CTD PMID:20823114 NCBI chr 4:44,573,264...44,580,640
Ensembl chr 4:44,573,264...44,580,638
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Bucladesine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein] CTD PMID:12538206 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
JBrowse link
G Ccn2 cellular communication network factor 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CCN2 mRNA CTD PMID:20823114 NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CCNB1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CCNB1 protein CTD PMID:22534328 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 increases expression
multiple interactions
EXP
ISO
Bucladesine results in increased expression of CCND1 protein
[Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] affects the expression of CCND1 protein; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in decreased expression of CCND1 protein
CTD PMID:16718685, PMID:21693435, PMID:22534328 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd3 cyclin D3 increases expression EXP Bucladesine results in increased expression of CCND3 protein CTD PMID:16718685 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Cd69 Cd69 molecule decreases expression ISO Bucladesine results in decreased expression of CD69 protein CTD PMID:25433234 NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
JBrowse link
G Cd80 Cd80 molecule multiple interactions ISO Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of CD80 protein] CTD PMID:12538815 NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
JBrowse link
G Cdc42bpa CDC42 binding protein kinase alpha multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CDC42BPA mRNA CTD PMID:20823114 NCBI chr13:98,231,326...98,447,762
Ensembl chr13:98,231,326...98,447,762
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
EXP
ISO
Bucladesine results in increased expression of CDKN1A protein
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of CDKN1A mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of CDKN1A protein
GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]
CTD PMID:16718685, PMID:20823114, PMID:22534328 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B increases expression EXP Bucladesine results in increased expression of CDKN1B protein CTD PMID:16718685, PMID:21693435 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta increases expression
multiple interactions
ISO Bucladesine results in increased expression of CEBPB protein
Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of CEBPB protein]
CTD PMID:19282384, PMID:19698295 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
JBrowse link
G Cebpz CCAAT/enhancer binding protein zeta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CEBPZ mRNA CTD PMID:20823114 NCBI chr 6:1,516,804...1,534,488
Ensembl chr 6:1,516,804...1,534,488
JBrowse link
G Chat choline O-acetyltransferase multiple interactions
increases expression
ISO
EXP
[Bucladesine co-treated with Tretinoin] results in increased activity of CHAT protein; [Tretinoin co-treated with Bucladesine] results in increased activity of CHAT protein
Bucladesine results in increased expression of CHAT protein
Nicotine promotes the reaction [Bucladesine results in increased expression of CHAT protein]
CTD PMID:16724269, PMID:20361958, PMID:29665406 NCBI chr16:8,576,858...8,686,131
Ensembl chr16:8,577,840...8,686,131
JBrowse link
G Cldn5 claudin 5 increases expression ISO Bucladesine results in increased expression of CLDN5 mRNA CTD PMID:20711499 NCBI chr11:86,356,292...86,357,718
Ensembl chr11:86,356,294...86,357,718
JBrowse link
G Cngb1 cyclic nucleotide gated channel subunit beta 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CNGB1 mRNA CTD PMID:20823114 NCBI chr19:10,142,440...10,206,618
Ensembl chr19:10,142,496...10,206,681
JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] CTD PMID:11576339, PMID:16430859 NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
JBrowse link
G Col3a1 collagen type III alpha 1 chain multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] CTD PMID:11576339 NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
JBrowse link
G Col6a2 collagen type VI alpha 2 chain multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A2 mRNA CTD PMID:20823114 NCBI chr20:12,773,472...12,801,179
Ensembl chr20:12,773,427...12,801,180
JBrowse link
G Col6a3 collagen type VI alpha 3 chain multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of COL6A3 mRNA CTD PMID:20823114 NCBI chr 9:97,926,784...98,004,643
Ensembl chr 9:97,926,787...98,004,546
JBrowse link
G Cox6a2 cytochrome c oxidase subunit 6A2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of COX6A2 mRNA CTD PMID:20823114 NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
JBrowse link
G Cplx1 complexin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CPLX1 mRNA CTD PMID:20823114 NCBI chr14:2,194,895...2,226,610
Ensembl chr14:2,194,933...2,226,598
JBrowse link
G Creb1 cAMP responsive element binding protein 1 increases phosphorylation
multiple interactions
ISO Bucladesine results in increased phosphorylation of CREB1 protein
Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased phosphorylation of CREB1 protein]]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of CREB1 protein]
CTD PMID:12164941, PMID:18787026, PMID:19282384 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Crebbp CREB binding protein multiple interactions ISO Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]
[Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]
CTD PMID:19282384, PMID:20685861 NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
JBrowse link
G Crem cAMP responsive element modulator multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CREM mRNA CTD PMID:20823114 NCBI chr17:57,021,704...57,090,888
Ensembl chr17:57,031,766...57,090,888
JBrowse link
G Cryab crystallin, alpha B multiple interactions EXP Bucladesine inhibits the reaction [arsenite results in increased expression of CRYAB protein] CTD PMID:8769853 NCBI chr 8:55,178,543...55,182,546
Ensembl chr 8:55,178,289...55,182,545
JBrowse link
G Csf1r colony stimulating factor 1 receptor multiple interactions ISO Bucladesine promotes the reaction [Tretinoin results in increased expression of CSF1R mRNA] CTD PMID:8445950 NCBI chr18:56,414,493...56,458,300
Ensembl chr18:56,414,488...56,458,300
JBrowse link
G Ctbp1 C-terminal binding protein 1 multiple interactions
affects localization
ISO Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein]; Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]; Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein]
Bucladesine affects the localization of CTBP1 protein
CTD PMID:18184656 NCBI chr14:82,762,109...82,789,350
Ensembl chr14:82,762,190...82,789,319
JBrowse link
G Ctbp2 C-terminal binding protein 2 affects localization
multiple interactions
ISO Bucladesine affects the localization of CTBP2 protein
Bucladesine promotes the reaction [CTBP1 protein binds to CTBP2 protein]
CTD PMID:18184656 NCBI chr 1:205,001,354...205,030,565
Ensembl chr 1:205,001,396...205,040,755
JBrowse link
G Ctnnb1 catenin beta 1 increases phosphorylation EXP Bucladesine results in increased phosphorylation of CTNNB1 protein CTD PMID:26964897 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Ctps2 CTP synthase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of CTPS2 mRNA CTD PMID:20823114 NCBI chr  X:33,383,087...33,522,852
Ensembl chr  X:33,383,087...33,522,836
JBrowse link
G Cxcl12 C-X-C motif chemokine ligand 12 decreases expression ISO Bucladesine results in decreased expression of CXCL12 mRNA CTD PMID:20711499 NCBI chr 4:149,261,044...149,273,891
Ensembl chr 4:149,261,044...149,273,891
JBrowse link
G Cyb5d1 cytochrome b5 domain containing 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of CYB5D1 mRNA CTD PMID:20823114 NCBI chr10:55,993,206...55,997,429
Ensembl chr10:55,995,823...55,997,299
JBrowse link
G Cyp11a1 cytochrome P450, family 11, subfamily a, polypeptide 1 increases expression
multiple interactions
EXP
ISO
Bucladesine results in increased expression of CYP11A1 mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of CYP11A1 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP11A1 mRNA]
CTD PMID:21693180, PMID:21979172, PMID:23200735 NCBI chr 8:62,798,317...62,809,848
Ensembl chr 8:62,779,875...62,809,893
JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression
increases expression
multiple interactions
EXP Bucladesine results in decreased expression of CYP17A1 mRNA
Bucladesine results in increased expression of CYP17A1 mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of CYP17A1 mRNA]
CTD PMID:21458522, PMID:21693180, PMID:23200735 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 multiple interactions EXP
ISO
Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; Bucladesine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]
Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
CTD PMID:1849469, PMID:16901605 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 multiple interactions ISO Bucladesine affects the reaction [Benzo(a)pyrene results in increased expression of CYP1A2 mRNA] CTD PMID:1849469 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 increases expression ISO Bucladesine results in increased expression of CYP1B1 mRNA CTD PMID:11559018 NCBI chr 6:2,308,179...2,316,739
Ensembl chr 6:2,307,808...2,316,722
JBrowse link
G Cyp2a3 cytochrome P450, family 2, subfamily a, polypeptide 3 increases expression
multiple interactions
ISO Bucladesine results in increased expression of CYP2A5 mRNA
NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]
CTD PMID:11162586, PMID:22859313 NCBI chr 1:83,653,248...83,662,118
Ensembl chr 1:83,653,234...83,766,484
JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO Bucladesine promotes the reaction [CYP2E1 protein results in increased oxidation of 4-nitrophenol] CTD PMID:8531136 NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
JBrowse link
G Dcn decorin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DCN protein] CTD PMID:20823114 NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
JBrowse link
G Ddx27 DEAD-box helicase 27 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of DDX27 mRNA CTD PMID:20823114 NCBI chr 3:163,767,236...163,786,408
Ensembl chr 3:163,767,173...163,786,445
JBrowse link
G Des desmin multiple interactions EXP
ISO
[Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of DES mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of DES mRNA
CTD PMID:19089455, PMID:20823114 NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294
JBrowse link
G Dhx9 DExH-box helicase 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DHX9 mRNA CTD PMID:20823114 NCBI chr13:70,885,503...70,922,278
Ensembl chr13:70,885,504...70,922,245
JBrowse link
G Dio2 iodothyronine deiodinase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DIO2 mRNA CTD PMID:20823114 NCBI chr 6:114,475,156...114,489,443
Ensembl chr 6:114,476,142...114,476,723
JBrowse link
G Dtymk deoxythymidylate kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of DTYMK mRNA CTD PMID:20823114 NCBI chr 9:100,921,565...100,930,399
Ensembl chr 9:100,921,565...100,930,399
JBrowse link
G Eda ectodysplasin-A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EDA mRNA CTD PMID:20823114 NCBI chr  X:69,730,123...70,222,693
Ensembl chr  X:69,730,242...70,220,329
JBrowse link
G Eef1a1 eukaryotic translation elongation factor 1 alpha 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EEF1A1 mRNA CTD PMID:20823114 NCBI chr 8:85,838,594...85,841,816
Ensembl chr 8:85,838,869...85,840,818
JBrowse link
G Efemp1 EGF containing fibulin extracellular matrix protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EFEMP1 mRNA CTD PMID:20823114 NCBI chr14:113,202,382...113,294,993
Ensembl chr14:113,202,419...113,295,014
JBrowse link
G Egf epidermal growth factor multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egr2 early growth response 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EGR2 mRNA CTD PMID:20823114 NCBI chr20:22,452,170...22,461,018
Ensembl chr20:22,454,463...22,459,025
JBrowse link
G Eno2 enolase 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA CTD PMID:29698629 NCBI chr 4:157,285,192...157,294,090
Ensembl chr 4:157,285,179...157,294,047
JBrowse link
G Epb41l4a erythrocyte membrane protein band 4.1 like 4A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPB41L4A mRNA CTD PMID:20823114 NCBI chr18:26,570,051...26,788,586
Ensembl chr18:26,570,647...26,658,892
JBrowse link
G Epha3 Eph receptor A3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of EPHA3 mRNA CTD PMID:20823114 NCBI chr11:421,253...783,037
Ensembl chr11:421,135...782,954
JBrowse link
G Esr1 estrogen receptor 1 increases expression
multiple interactions
EXP Bucladesine results in increased expression of ESR1 mRNA
[Quercetin co-treated with Bucladesine] results in increased expression of ESR1 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of ESR1 mRNA]
CTD PMID:21693180, PMID:23200735 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Eya1 EYA transcriptional coactivator and phosphatase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of EYA1 mRNA CTD PMID:20823114 NCBI chr 5:4,275,728...4,495,525
Ensembl chr 5:4,373,626...4,513,142
JBrowse link
G Fads2 fatty acid desaturase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FADS2 mRNA CTD PMID:20823114 NCBI chr 1:225,906,582...226,152,568
Ensembl chr 1:226,114,413...226,152,524
JBrowse link
G Fas Fas cell surface death receptor increases expression
multiple interactions
EXP Bucladesine results in increased expression of FAS mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of FAS mRNA]
CTD PMID:12414803 NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
JBrowse link
G Fbxo11 F-box protein 11 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXO11 mRNA CTD PMID:20823114 NCBI chr 6:11,662,356...11,737,427
Ensembl chr 6:11,662,356...11,686,682
JBrowse link
G Fbxw5 F-box and WD repeat domain containing 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FBXW5 mRNA CTD PMID:20823114 NCBI chr 3:2,726,705...2,731,213
Ensembl chr 3:2,727,254...2,731,212
JBrowse link
G Fcer2 Fc fragment of IgE receptor II decreases expression ISO Bucladesine results in decreased expression of FCER2 protein CTD PMID:1328389 NCBI chr12:2,233,772...2,245,324
Ensembl chr12:2,233,778...2,245,324
JBrowse link
G Fgd1 FYVE, RhoGEF and PH domain containing 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FGD1 mRNA CTD PMID:20823114 NCBI chr  X:20,100,942...20,143,871
Ensembl chr  X:20,216,587...20,225,955
Ensembl chr  X:20,216,587...20,225,955
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Filip1l filamin A interacting protein 1-like multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FILIP1L mRNA CTD PMID:20823114 NCBI chr11:45,039,488...45,275,141
Ensembl chr11:45,039,461...45,124,423
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 multiple interactions ISO [bisphenol A co-treated with Bucladesine] results in increased methylation of FKBP5 intron; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 protein; [Bucladesine co-treated with Dexamethasone] results in increased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA; [Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 protein; [fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron; bisphenol A promotes the reaction [[fulvestrant co-treated with Bucladesine] results in increased methylation of FKBP5 intron]; Dexamethasone inhibits the reaction [[Bucladesine co-treated with bisphenol A] results in decreased expression of FKBP5 mRNA]; Estradiol inhibits the reaction [[Bucladesine co-treated with fulvestrant] results in decreased expression of FKBP5 mRNA] CTD PMID:26427651 NCBI chr20:7,976,704...8,097,290
Ensembl chr20:7,976,713...8,019,020
JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of FN1 mRNA CTD PMID:20823114 NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit affects expression
multiple interactions
increases expression
ISO Bucladesine affects the expression of FOS protein
Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of FOS protein]
Bucladesine results in increased expression of FOS mRNA; Bucladesine results in increased expression of FOS protein
CTD PMID:7798212, PMID:9187264, PMID:19282384 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Foxo1 forkhead box O1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of FOXO1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FOXO1 mRNA CTD PMID:20823114 NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
JBrowse link
G Fscn2 fascin actin-bundling protein 2, retinal multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of FSCN2 mRNA CTD PMID:20823114 NCBI chr10:109,528,307...109,540,675
Ensembl chr10:109,533,487...109,540,026
JBrowse link
G G6pc glucose-6-phosphatase, catalytic subunit increases expression
multiple interactions
ISO Bucladesine results in increased expression of G6PC mRNA; Bucladesine results in increased expression of G6PC protein
IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC mRNA]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]]
CTD PMID:22859313, PMID:26064446 NCBI chr10:89,286,009...89,296,213
Ensembl chr10:89,285,855...89,296,213
JBrowse link
G Gars glycyl-tRNA synthetase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GARS1 mRNA CTD PMID:20823114 NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
JBrowse link
G Gbe1 1,4-alpha-glucan branching enzyme 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GBE1 mRNA CTD PMID:20823114 NCBI chr11:7,210,169...7,485,895
Ensembl chr11:7,210,209...7,485,890
JBrowse link
G Gbp2 guanylate binding protein 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GBP2 mRNA CTD PMID:20823114 NCBI chr 2:248,276,795...248,293,784
Ensembl chr 2:248,276,709...248,293,784
JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 (I blood group) multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GCNT2 mRNA CTD PMID:20823114 NCBI chr17:21,634,546...21,677,477
Ensembl chr17:21,634,551...21,739,408
JBrowse link
G Gdf3 growth differentiation factor 3 affects expression
multiple interactions
ISO Bucladesine affects the expression of GDF3 mRNA; Bucladesine affects the expression of GDF3 protein
bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of GDF3 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of GDF3 protein]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of GDF3 protein]
CTD PMID:31400064 NCBI chr 4:155,417,667...155,422,014
Ensembl chr 4:155,417,004...155,421,998
JBrowse link
G Gipc1 GIPC PDZ domain containing family, member 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GIPC1 mRNA CTD PMID:20823114 NCBI chr19:24,786,604...24,798,231
Ensembl chr19:24,786,628...24,798,233
JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions
increases expression
EXP GJA1 promotes the reaction [Bucladesine results in increased expression of CDKN1A protein]; Tolbutamide promotes the reaction [Bucladesine results in increased expression of GJA1 protein] CTD PMID:11741589, PMID:16718685 NCBI chr20:37,876,650...37,889,097
Ensembl chr20:37,876,650...37,889,089
JBrowse link
G Gpd1 glycerol-3-phosphate dehydrogenase 1 multiple interactions ISO Bucladesine promotes the reaction [Bezafibrate results in increased expression of GPD1 mRNA] CTD PMID:1976021 NCBI chr 7:141,368,928...141,377,931
Ensembl chr 7:141,370,491...141,377,928
JBrowse link
G Gpkow G patch domain and KOW motifs multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of GPKOW mRNA CTD PMID:20823114 NCBI chr  X:15,636,567...15,651,332
Ensembl chr  X:15,636,563...15,651,332
JBrowse link
G Gpnmb glycoprotein nmb multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of GPNMB mRNA CTD PMID:20823114 NCBI chr 4:78,694,447...78,715,685
Ensembl chr 4:78,694,447...78,715,683
JBrowse link
G Gsta1 glutathione S-transferase alpha 1 multiple interactions
increases expression
ISO KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA1 mRNA] CTD PMID:26049102 NCBI chr 9:27,366,404...27,381,004
Ensembl chr 9:27,368,272...27,452,902
JBrowse link
G Gsta2 glutathione S-transferase alpha 2 increases expression
multiple interactions
ISO Bucladesine results in increased expression of GSTA2 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA2 mRNA]
CTD PMID:26049102 NCBI chr 8:85,640,081...85,645,621 JBrowse link
G Gsta4 glutathione S-transferase alpha 4 increases expression
multiple interactions
ISO Bucladesine results in increased expression of GSTA4 mRNA
KT 5720 inhibits the reaction [Bucladesine results in increased expression of GSTA4 mRNA]
CTD PMID:26049102 NCBI chr 8:85,497,557...85,514,732
Ensembl chr 8:85,497,557...85,518,879
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Bucladesine results in increased expression of HIF1A mRNA CTD PMID:18591213 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hoxa1 homeobox A1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of HOXA1 mRNA] CTD PMID:20823114 NCBI chr 4:82,124,358...82,127,182
Ensembl chr 4:82,125,406...82,127,066
JBrowse link
G Hsd17b12 hydroxysteroid (17-beta) dehydrogenase 12 increases expression EXP Bucladesine results in increased expression of HSD17B12 mRNA CTD PMID:21458522 NCBI chr 3:82,924,699...83,048,465
Ensembl chr 3:82,924,687...83,048,435
JBrowse link
G Hsd3b1 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 increases expression EXP Bucladesine results in increased expression of HSD3B1 mRNA CTD PMID:21458522
G Hspb1 heat shock protein family B (small) member 1 increases expression
increases phosphorylation
EXP
ISO
Bucladesine results in increased expression of HSP27 protein
Bucladesine results in increased phosphorylation of HSPB1 protein
CTD PMID:7541446, PMID:10559386 NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
JBrowse link
G Htr1a 5-hydroxytryptamine receptor 1A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of HTR1A mRNA CTD PMID:20823114 NCBI chr 2:36,246,628...36,247,896
Ensembl chr 2:36,246,628...36,247,896
JBrowse link
G Iapp islet amyloid polypeptide increases expression EXP Bucladesine results in increased expression of IAPP mRNA CTD PMID:9142872 NCBI chr 4:176,509,863...176,517,903
Ensembl chr 4:176,510,696...176,516,083
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions ISO Bucladesine inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein] CTD PMID:12538815 NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
JBrowse link
G Id1 inhibitor of DNA binding 1, HLH protein increases expression
multiple interactions
ISO Bucladesine results in increased expression of ID1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of ID1 mRNA]
CTD PMID:20522807 NCBI chr 3:148,214,623...148,216,715
Ensembl chr 3:148,215,540...148,216,718
JBrowse link
G Ifrd2 interferon-related developmental regulator 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IFRD2 mRNA CTD PMID:20823114 NCBI chr 8:116,343,096...116,348,318
Ensembl chr 8:116,343,096...116,348,314
JBrowse link
G Igf1 insulin-like growth factor 1 multiple interactions ISO Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]; FGF9 protein inhibits the reaction [Bucladesine promotes the reaction [IGF1 protein results in increased abundance of Estradiol]]; FGF9 protein inhibits the reaction [IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone]]; IGF1 protein promotes the reaction [Bucladesine results in increased abundance of Progesterone] CTD PMID:22798350 NCBI chr 7:28,412,123...28,491,815
Ensembl chr 7:28,412,198...28,486,609
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 increases expression
multiple interactions
ISO Bucladesine results in increased expression of IGFBP1
[Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 mRNA]; Azacitidine promotes the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP1 protein]
CTD PMID:12093828, PMID:20823114, PMID:30328349 NCBI chr14:87,448,716...87,453,783
Ensembl chr14:87,448,692...87,453,785
JBrowse link
G Igfbp3 insulin-like growth factor binding protein 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP3 mRNA CTD PMID:20823114 NCBI chr14:87,457,647...87,465,374
Ensembl chr14:87,457,647...87,465,374
JBrowse link
G Igfbp4 insulin-like growth factor binding protein 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IGFBP4 mRNA CTD PMID:20823114 NCBI chr10:86,950,555...86,962,563
Ensembl chr10:86,950,557...86,962,578
JBrowse link
G Ighe immunoglobulin heavy constant epsilon multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]] CTD PMID:12230500 NCBI chr 6:138,066,728...138,068,606 JBrowse link
G Il10 interleukin 10 decreases expression
multiple interactions
ISO Bucladesine results in decreased expression of IL10
Bucladesine promotes the reaction [Zymosan results in increased expression of IL10 protein]
CTD PMID:11301049, PMID:19273625 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
JBrowse link
G Il12b interleukin 12B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IL12B mRNA CTD PMID:20823114 NCBI chr10:30,034,447...30,048,774
Ensembl chr10:30,038,709...30,048,085
JBrowse link
G Il13 interleukin 13 decreases expression
decreases secretion
ISO Bucladesine results in decreased expression of IL13 mRNA
Bucladesine results in decreased secretion of IL13 protein
CTD PMID:16083514 NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]; Dipyridamole promotes the reaction [Bucladesine promotes the reaction [IL1B protein results in increased abundance of Nitrites]] CTD PMID:8904084 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il22 interleukin 22 multiple interactions ISO dorsomorphin affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased abundance of Glucose]]; IL22 protein inhibits the reaction [Bucladesine results in increased abundance of Glucose]; IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]; IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]] CTD PMID:26064446 NCBI chr 7:61,236,037...61,240,502
Ensembl chr 7:61,236,037...61,240,502
JBrowse link
G Il23a interleukin 23 subunit alpha increases expression
multiple interactions
ISO Bucladesine results in increased expression of IL23A mRNA
[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of IL23A mRNA
CTD PMID:19273625, PMID:20823114 NCBI chr 7:2,710,609...2,712,723
Ensembl chr 7:2,710,609...2,712,723
JBrowse link
G Il2ra interleukin 2 receptor subunit alpha decreases expression ISO Bucladesine results in decreased expression of IL2RA protein CTD PMID:1709825, PMID:25433234 NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
JBrowse link
G Il4 interleukin 4 multiple interactions ISO Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA alternative form]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [IL4 protein results in increased expression of IGHE mRNA]]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL4 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL4 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL4 protein] CTD PMID:11886533, PMID:12230500 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531
JBrowse link
G Il5 interleukin 5 multiple interactions ISO Bucladesine inhibits the reaction [Itraconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Itraconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Ketoconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Ketoconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Miconazole results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Miconazole results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [terbinafine results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [terbinafine results in decreased secretion of IL5 protein]; Bucladesine inhibits the reaction [Tolnaftate results in decreased expression of IL5 mRNA]; Bucladesine inhibits the reaction [Tolnaftate results in decreased secretion of IL5 protein] CTD PMID:11886533 NCBI chr10:39,066,716...39,069,587
Ensembl chr10:39,066,716...39,069,587
JBrowse link
G Il6 interleukin 6 multiple interactions ISO [Bucladesine co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] CTD PMID:20388727 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Inha inhibin subunit alpha decreases expression
multiple interactions
EXP Bucladesine results in decreased expression of INHA mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA; Atrazine inhibits the reaction [Bucladesine results in decreased expression of INHA mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INHA mRNA]
CTD PMID:21693180, PMID:23200735 NCBI chr 9:82,700,482...82,703,383
Ensembl chr 9:82,700,468...82,703,400
JBrowse link
G Insl3 insulin-like 3 multiple interactions
increases expression
EXP [Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of INSL3 mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of INSL3 mRNA] CTD PMID:21458522, PMID:21693180, PMID:23200735 NCBI chr16:20,120,753...20,122,702
Ensembl chr16:20,121,352...20,122,696
JBrowse link
G Ints7 integrator complex subunit 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of INTS7 mRNA CTD PMID:20823114 NCBI chr13:110,257,571...110,310,413
Ensembl chr13:110,257,571...110,310,413
JBrowse link
G Irf9 interferon regulatory factor 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of IRF9 mRNA CTD PMID:20823114 NCBI chr15:34,282,936...34,288,981
Ensembl chr15:34,282,936...34,288,138
JBrowse link
G Isg20l2 interferon stimulated exonuclease gene 20-like 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ISG20L2 mRNA CTD PMID:20823114 NCBI chr 2:187,302,192...187,311,677
Ensembl chr 2:187,302,192...187,311,676
JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of ITGB1 mRNA CTD PMID:20823114 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
ISO Bucladesine results in increased expression of JUN mRNA; Bucladesine results in increased expression of JUN protein
Bucladesine results in increased expression of JUN protein; Bucladesine results in increased expression of JUN protein modified form
Bucladesine promotes the reaction [JUN protein binds to ABCC2 promoter]; Bucladesine promotes the reaction [JUN protein binds to ATF2 protein]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein modified form]; KT 5720 inhibits the reaction [Bucladesine results in increased expression of JUN protein]
[Bucladesine co-treated with ciglitazone] results in increased expression of and results in increased phosphorylation of JUN protein; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of JUN mRNA]; Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein; ciglitazone promotes the reaction [Bucladesine results in increased expression of JUN mRNA]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of JUN protein]
CTD PMID:9187264, PMID:18755854, PMID:19282384, PMID:19698295, PMID:26049102 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Kat2a lysine acetyltransferase 2A multiple interactions ISO Bucladesine inhibits the reaction [CTBP1 protein binds to KAT2A protein] CTD PMID:18184656 NCBI chr10:88,611,586...88,619,558
Ensembl chr10:88,611,586...88,619,537
JBrowse link
G Kcnc4 potassium voltage-gated channel subfamily C member 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KCNC4 mRNA CTD PMID:20823114 NCBI chr 2:210,220,908...210,241,447
Ensembl chr 2:210,220,908...210,241,455
JBrowse link
G Kng2 kininogen 2 increases activity EXP Bucladesine results in increased activity of KNG1 CTD PMID:1334751 NCBI chr11:81,509,185...81,516,759 JBrowse link
G Krt8 keratin 8 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA; Azacitidine inhibits the reaction [[Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of KRT8 mRNA] CTD PMID:20823114 NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
JBrowse link
G Lamb2 laminin subunit beta 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LAMB2 mRNA CTD PMID:20823114 NCBI chr 8:117,268,335...117,280,517
Ensembl chr 8:117,268,337...117,280,517
JBrowse link
G Ldha lactate dehydrogenase A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LDHA mRNA CTD PMID:20823114 NCBI chr 1:102,900,288...102,909,713
Ensembl chr 1:102,900,286...102,909,707
JBrowse link
G Lep leptin decreases expression ISO Bucladesine results in decreased expression of LEP mRNA CTD PMID:9002984 NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
JBrowse link
G Lgals3 galectin 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of LGALS3 mRNA CTD PMID:20823114 NCBI chr15:24,153,602...24,165,537
Ensembl chr15:24,141,651...24,165,537
JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor decreases expression
multiple interactions
EXP Bucladesine results in decreased expression of LHCGR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of LHCGR mRNA]
CTD PMID:21693180, PMID:23200735 NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
JBrowse link
G Lipe lipase E, hormone sensitive type affects localization
increases activity
increases expression
multiple interactions
EXP
ISO
Bucladesine affects the localization of LIPE protein
Bucladesine results in increased activity of LIPE protein
Bucladesine results in increased expression of LIPE mRNA
[Bucladesine co-treated with LIPE protein] results in increased expression of ABCA1 protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein; CAY 10499 inhibits the reaction [Bucladesine results in increased activity of and results in increased phosphorylation of LIPE protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of LIPE protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of LIPE mRNA]; NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]; NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]]
CTD PMID:11160373, PMID:23362264 NCBI chr 1:82,248,031...82,266,727
Ensembl chr 1:82,248,046...82,266,727
JBrowse link
G Lpar3 lysophosphatidic acid receptor 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LPAR3 mRNA CTD PMID:20823114 NCBI chr 2:252,090,634...252,159,221
Ensembl chr 2:252,090,669...252,159,903
JBrowse link
G Ltbp1 latent transforming growth factor beta binding protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of LTBP1 mRNA CTD PMID:20823114 NCBI chr 6:21,203,502...21,600,441
Ensembl chr 6:21,203,502...21,600,451
JBrowse link
G Ltc4s leukotriene C4 synthase decreases secretion ISO Bucladesine results in decreased secretion of LTC4S protein CTD PMID:16083514 NCBI chr10:35,736,486...35,743,088
Ensembl chr10:35,737,664...35,739,625
JBrowse link
G Map1a microtubule-associated protein 1A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MAP1A mRNA CTD PMID:20823114 NCBI chr 3:113,251,918...113,272,193
Ensembl chr 3:113,251,778...113,272,186
JBrowse link
G Map2 microtubule-associated protein 2 multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA CTD PMID:29698629 NCBI chr 9:73,204,753...73,462,965
Ensembl chr 9:73,319,710...73,462,972
JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MAP4K4 mRNA CTD PMID:20823114 NCBI chr 9:46,657,444...46,782,545
Ensembl chr 9:46,657,575...46,782,545
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
ISO 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK1 protein
Bucladesine results in increased phosphorylation of MAPK1 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK1 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK1 protein]]
CTD PMID:8526880, PMID:19282384, PMID:22875961 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
ISO 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol promotes the reaction [[1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein]; [1-Methyl-3-isobutylxanthine co-treated with Bucladesine] results in increased activity of MAPK3 protein
Bucladesine results in increased phosphorylation of MAPK3 protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Bucladesine results in increased phosphorylation of MAPK3 protein]; Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of and results in increased activity of MAPK3 protein]]
CTD PMID:8526880, PMID:19282384, PMID:22875961 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mgat4b alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MGAT4B mRNA CTD PMID:20823114 NCBI chr10:35,726,501...35,736,338
Ensembl chr10:35,726,544...35,736,338
JBrowse link
G Mir125a microRNA 125a decreases expression EXP
ISO
Bucladesine results in decreased expression of MIR125A mRNA CTD PMID:23045399 NCBI chr 1:59,704,827...59,704,911
Ensembl chr 1:59,704,827...59,704,911
JBrowse link
G Mir145 microRNA 145 decreases expression EXP
ISO
Bucladesine results in decreased expression of MIR145 mRNA CTD PMID:23045399 NCBI chr18:56,969,907...56,969,994
Ensembl chr18:56,969,907...56,969,994
JBrowse link
G Mir27b microRNA 27b multiple interactions ISO [Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MIR27B mRNA CTD PMID:30328349 NCBI chr17:823,461...823,557
Ensembl chr17:823,461...823,557
JBrowse link
G Mir455 microRNA 455 decreases expression EXP
ISO
Bucladesine results in decreased expression of MIR455 mRNA CTD PMID:23045399 NCBI chr 5:79,097,208...79,097,285
Ensembl chr 5:79,097,208...79,097,285
JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression EXP Bucladesine results in decreased expression of MKI67 protein CTD PMID:16718685 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of MMP2 mRNA CTD PMID:20823114 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mthfd2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTHFD2 mRNA CTD PMID:20823114 NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
JBrowse link
G Mtr 5-methyltetrahydrofolate-homocysteine methyltransferase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MTR mRNA CTD PMID:20823114 NCBI chr17:66,210,444...66,295,014
Ensembl chr17:66,210,461...66,295,014
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO Bucladesine results in decreased expression of MYC mRNA; Bucladesine results in decreased expression of MYC protein CTD PMID:7798212, PMID:9187264 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Myh9 myosin, heavy chain 9 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYH9 mRNA CTD PMID:20823114 NCBI chr 7:118,740,005...118,792,507
Ensembl chr 7:118,741,110...118,792,625
JBrowse link
G Myl12a myosin light chain 12A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12A mRNA CTD PMID:20823114 NCBI chr 9:119,325,282...119,333,012
Ensembl chr 9:119,325,283...119,332,967
JBrowse link
G Myl12b myosin light chain 12B multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYL12B mRNA CTD PMID:20823114 NCBI chr 9:119,307,168...119,321,500
Ensembl chr 9:119,307,176...119,321,500
JBrowse link
G Mylk myosin light chain kinase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYLK mRNA CTD PMID:20823114 NCBI chr11:69,013,060...69,260,039
Ensembl chr11:69,013,050...69,223,158
JBrowse link
G Myof myoferlin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of MYOF mRNA CTD PMID:20823114 NCBI chr 1:256,585,410...256,734,727
Ensembl chr 1:256,585,410...256,734,730
JBrowse link
G Ncf1 neutrophil cytosolic factor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NCF1 mRNA CTD PMID:20823114 NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
JBrowse link
G Ndst1 N-deacetylase and N-sulfotransferase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NDST1 mRNA CTD PMID:20823114 NCBI chr18:55,951,497...56,014,107
Ensembl chr18:55,955,389...55,992,885
JBrowse link
G Nefl neurofilament light multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA CTD PMID:29698629 NCBI chr15:44,799,378...44,803,251
Ensembl chr15:44,799,334...44,804,574
JBrowse link
G Nefm neurofilament medium multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr15:44,855,307...44,860,604
Ensembl chr15:44,855,310...44,860,604
JBrowse link
G Neurog1 neurogenin 1 multiple interactions
affects expression
ISO bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of NEUROG1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of NEUROG1 protein]
Bucladesine affects the expression of NEUROG1 mRNA; Bucladesine affects the expression of NEUROG1 protein
CTD PMID:31400064 NCBI chr17:9,154,656...9,156,175
Ensembl chr17:9,154,656...9,156,175
JBrowse link
G Nexn nexilin (F actin binding protein) multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NEXN mRNA CTD PMID:20823114 NCBI chr 2:257,452,937...257,484,607
Ensembl chr 2:257,453,347...257,484,587
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions
increases response to substance
ISO [NFE2L2 gene mutant form results in increased susceptibility to Bucladesine] which results in increased expression of ALAS1 mRNA; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of CYP2A5 mRNA]; NFE2L2 gene mutant form promotes the reaction [Bucladesine results in increased expression of G6PC mRNA] CTD PMID:22859313 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Ngf nerve growth factor multiple interactions ISO [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of ENO2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of MAP2 mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFL mRNA; [Bucladesine co-treated with 1-Methyl-3-isobutylxanthine co-treated with EGF protein co-treated with FGF2 protein co-treated with NGF protein co-treated with BDNF protein] results in increased expression of NEFM mRNA CTD PMID:29698629 NCBI chr 2:204,886,158...204,939,523
Ensembl chr 2:204,886,202...204,940,453
JBrowse link
G Nom1 nucleolar protein with MIF4G domain 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NOM1 mRNA CTD PMID:20823114 NCBI chr 4:2,340,034...2,356,427
Ensembl chr 4:2,340,148...2,356,068
JBrowse link
G Nphp1 nephrocystin 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NPHP1 mRNA CTD PMID:20823114 NCBI chr 3:120,316,048...120,370,089
Ensembl chr 3:120,316,047...120,373,500
JBrowse link
G Nptxr neuronal pentraxin receptor multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NPTXR mRNA CTD PMID:20823114 NCBI chr 7:121,011,678...121,029,754
Ensembl chr 7:121,011,680...121,029,754
JBrowse link
G Npy neuropeptide Y increases expression EXP Bucladesine results in increased expression of NPY mRNA CTD PMID:19912776 NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
JBrowse link
G Nr0b1 nuclear receptor subfamily 0, group B, member 1 decreases expression
multiple interactions
ISO Bucladesine results in decreased expression of NR0B1 mRNA; Bucladesine results in decreased expression of NR0B1 protein
Cycloheximide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of NR0B1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in decreased expression of NR0B1 protein]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]
CTD PMID:18787026, PMID:19282384 NCBI chr  X:54,734,385...54,738,513
Ensembl chr  X:54,734,385...54,738,513
JBrowse link
G Nr1h2 nuclear receptor subfamily 1, group H, member 2 multiple interactions ISO NR1H2 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] CTD PMID:23362264 NCBI chr 1:100,554,577...100,559,896
Ensembl chr 1:100,554,544...100,559,942
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 multiple interactions ISO NR1H3 protein affects the reaction [Bucladesine results in increased phosphorylation of LIPE protein]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased phosphorylation of LIPE protein]] CTD PMID:23362264 NCBI chr 3:80,004,130...80,014,197
Ensembl chr 3:80,004,130...80,012,750
JBrowse link
G Nr2f1 nuclear receptor subfamily 2, group F, member 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NR2F1 mRNA CTD PMID:20823114 NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894
JBrowse link
G Nr4a1 nuclear receptor subfamily 4, group A, member 1 multiple interactions
increases expression
ISO NR0B1 protein inhibits the reaction [Bucladesine results in increased expression of NR4A1 protein]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of NR4A1 protein] CTD PMID:18787026, PMID:19282384 NCBI chr 7:142,899,358...142,920,216
Ensembl chr 7:142,905,758...142,920,216
JBrowse link
G Nr5a1 nuclear receptor subfamily 5, group A, member 1 multiple interactions ISO Bucladesine inhibits the reaction [CTBP1 protein binds to NR5A1 protein]
NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]
CTD PMID:18184656, PMID:18787026 NCBI chr 3:22,998,900...23,020,441
Ensembl chr 3:22,999,616...23,020,441
JBrowse link
G Nrip1 nuclear receptor interacting protein 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NRIP1 mRNA CTD PMID:20823114 NCBI chr11:14,658,225...14,742,478
Ensembl chr11:14,658,225...14,741,563
JBrowse link
G Nt5e 5' nucleotidase, ecto multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of NT5E mRNA CTD PMID:20823114 NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
JBrowse link
G Ntf3 neurotrophin 3 increases expression EXP Bucladesine results in increased expression of NTF3 protein CTD PMID:19854260 NCBI chr 4:158,636,883...158,705,886
Ensembl chr 4:158,636,884...158,705,886
JBrowse link
G Nts neurotensin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NTS mRNA CTD PMID:20823114 NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130
JBrowse link
G Nup155 nucleoporin 155 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of NUP155 mRNA CTD PMID:20823114 NCBI chr 2:57,206,665...57,258,242
Ensembl chr 2:57,206,613...57,258,295
JBrowse link
G Odc1 ornithine decarboxylase 1 multiple interactions
decreases activity
ISO 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone promotes the reaction [Bucladesine results in decreased activity of ODC1 protein] CTD PMID:6284819 NCBI chr 6:42,852,529...42,859,142
Ensembl chr 6:42,852,683...42,859,927
JBrowse link
G Ogfrl1 opioid growth factor receptor-like 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OGFRL1 mRNA CTD PMID:20823114 NCBI chr 9:29,634,178...29,647,903
Ensembl chr 9:29,634,179...29,647,903
JBrowse link
G Olr1201 olfactory receptor 1201 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of OR8B8 mRNA CTD PMID:20823114 NCBI chr 8:40,383,997...40,384,929
Ensembl chr 8:40,383,918...40,384,966
JBrowse link
G P4hb prolyl 4-hydroxylase subunit beta multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of P4HB mRNA CTD PMID:20823114 NCBI chr10:109,736,459...109,748,070
Ensembl chr10:109,736,458...109,747,987
JBrowse link
G Paep progestagen associated endometrial protein multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PAEP mRNA CTD PMID:20823114 NCBI chr 3:2,935,396...2,938,883 JBrowse link
G Pax6 paired box 6 multiple interactions
affects expression
ISO bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of PAX6 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of PAX6 protein]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of PAX6 protein]
Bucladesine affects the expression of PAX6 mRNA; Bucladesine affects the expression of PAX6 protein
CTD PMID:31400064 NCBI chr 3:95,700,241...95,728,682
Ensembl chr 3:95,707,386...95,728,624
JBrowse link
G Pcdh18 protocadherin 18 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDH18 mRNA CTD PMID:20823114 NCBI chr 2:138,819,957...138,833,932
Ensembl chr 2:138,819,960...138,833,933
JBrowse link
G Pcdhb5 protocadherin beta 5 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PCDHB4 mRNA CTD PMID:20823114 NCBI chr18:30,398,113...30,400,695
Ensembl chr18:30,398,113...30,400,695
JBrowse link
G Pck1 phosphoenolpyruvate carboxykinase 1 multiple interactions
increases expression
ISO
EXP
Metformin inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]
Lithium Chloride inhibits the reaction [Bucladesine results in increased expression of PCK1 mRNA]
CTD PMID:1371108, PMID:24428821 NCBI chr 3:171,213,936...171,219,885
Ensembl chr 3:171,213,936...171,219,871
JBrowse link
G Pdgfa platelet derived growth factor subunit A decreases expression ISO Bucladesine results in decreased expression of PDGFA mRNA CTD PMID:1650039 NCBI chr12:17,734,141...17,756,186
Ensembl chr12:17,734,133...17,755,285
JBrowse link
G Pdk1 pyruvate dehydrogenase kinase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PDK1 mRNA CTD PMID:20823114 NCBI chr 3:58,530,870...58,561,494
Ensembl chr 3:58,530,870...58,558,027
JBrowse link
G Pf4 platelet factor 4 increases expression
multiple interactions
ISO Bucladesine results in increased expression of PF4 mRNA
[Bucladesine co-treated with Tetrachlorodibenzodioxin] results in increased expression of PF4 mRNA
CTD PMID:21979172 NCBI chr14:18,848,549...18,849,258
Ensembl chr14:18,848,549...18,849,258
JBrowse link
G Pgrmc2 progesterone receptor membrane component 2 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PGRMC2 mRNA CTD PMID:20823114 NCBI chr 2:127,986,106...128,002,005
Ensembl chr 2:127,986,109...128,002,005
JBrowse link
G Pitpnc1 phosphatidylinositol transfer protein, cytoplasmic 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PITPNC1 mRNA CTD PMID:20823114 NCBI chr10:95,429,879...95,697,734 JBrowse link
G Pkd2l1 polycystin 2 like 1, transient receptor potential cation channel multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PKD2L1 mRNA CTD PMID:20823114 NCBI chr 1:263,922,201...263,959,318
Ensembl chr 1:263,922,201...263,959,318
JBrowse link
G Plat plasminogen activator, tissue type multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLAT mRNA CTD PMID:20823114 NCBI chr16:74,098,263...74,122,897
Ensembl chr16:74,098,260...74,122,889
JBrowse link
G Plekhg3 pleckstrin homology and RhoGEF domain containing G3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PLEKHG3 mRNA CTD PMID:20823114 NCBI chr 6:99,612,993...99,655,753
Ensembl chr 6:99,625,306...99,655,362
JBrowse link
G Plin1 perilipin 1 increases expression
multiple interactions
ISO Bucladesine results in increased expression of PLIN1 mRNA
LIPE protein affects the reaction [Bucladesine results in increased expression of PLIN1 mRNA]
CTD PMID:23362264 NCBI chr 1:141,458,907...141,470,927
Ensembl chr 1:141,458,181...141,471,010
JBrowse link
G Pls3 plastin 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PLS3 mRNA CTD PMID:20823114 NCBI chr  X:119,030,311...119,124,268
Ensembl chr  X:119,030,419...119,124,250
JBrowse link
G Pmp22 peripheral myelin protein 22 multiple interactions
increases activity
ISO Ascorbic Acid inhibits the reaction [Bucladesine results in increased activity of PMP22 promoter] CTD PMID:15034573 NCBI chr10:49,538,588...49,568,583
Ensembl chr10:49,538,588...49,568,583
JBrowse link
G Pnpla6 patatin-like phospholipase domain containing 6 increases expression
multiple interactions
ISO Bucladesine results in increased expression of PNPLA6 mRNA
Bucladesine results in increased expression of and results in increased activity of PNPLA6 protein; Cycloheximide inhibits the reaction [Bucladesine results in increased activity of PNPLA6 protein]
CTD PMID:20380879 NCBI chr12:2,068,749...2,098,139
Ensembl chr12:2,069,959...2,097,904
JBrowse link
G Pomc proopiomelanocortin increases expression ISO Bucladesine results in increased expression of POMC mRNA; Bucladesine results in increased expression of POMC protein modified form CTD PMID:1325994 NCBI chr 6:28,382,937...28,388,771
Ensembl chr 6:28,382,962...28,388,967
JBrowse link
G Pou5f1 POU class 5 homeobox 1 affects expression
multiple interactions
ISO Bucladesine affects the expression of POU5F1 mRNA; Bucladesine affects the expression of POU5F1 protein
bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of POU5F1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of POU5F1 protein]
CTD PMID:31400064 NCBI chr20:3,747,231...3,751,994
Ensembl chr20:3,747,221...3,751,994
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma increases expression
multiple interactions
ISO Bucladesine results in increased expression of PPARG protein
[ciglitazone co-treated with Bucladesine] affects the expression of PPARG mRNA; [ciglitazone co-treated with Bucladesine] results in increased expression of PPARG protein
CTD PMID:19698295 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Ppargc1a PPARG coactivator 1 alpha increases expression
multiple interactions
ISO Bucladesine results in increased expression of PPARGC1A mRNA; Bucladesine results in increased expression of PPARGC1A protein
IL22 protein inhibits the reaction [Bucladesine results in increased expression of PPARGC1A protein]; Metformin inhibits the reaction [Bucladesine results in increased expression of PPARGC1A mRNA]
CTD PMID:24428821, PMID:26064446 NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
JBrowse link
G Ppia peptidylprolyl isomerase A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PPIA mRNA CTD PMID:20823114 NCBI chr14:86,673,775...86,677,443
Ensembl chr14:86,673,775...86,677,443
JBrowse link
G Prima1 proline rich membrane anchor 1 increases expression EXP Bucladesine results in increased expression of PRIMA1 mRNA CTD PMID:18514641 NCBI chr 6:127,075,954...127,127,985
Ensembl chr 6:127,075,954...127,127,413
JBrowse link
G Prkaca protein kinase cAMP-activated catalytic subunit alpha multiple interactions
increases activity
EXP KT 5720 inhibits the reaction [Bucladesine results in increased activity of PRKACA protein] CTD PMID:31300867 NCBI chr19:25,095,089...25,118,869
Ensembl chr19:25,095,089...25,118,860
JBrowse link
G Prl prolactin multiple interactions ISO [Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate co-treated with Azacitidine] results in increased expression of PRL protein; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL mRNA; [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PRL protein CTD PMID:20823114, PMID:30328349 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
JBrowse link
G Prss12 serine protease 12 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of PRSS12 mRNA CTD PMID:20823114 NCBI chr 2:227,657,983...227,717,884
Ensembl chr 2:227,657,983...227,717,884
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 mRNA]]; Bucladesine inhibits the reaction [Ketoconazole inhibits the reaction [Dinoprostone results in increased expression of PTGS2 protein]]; Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
Bucladesine promotes the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]
CTD PMID:11095985, PMID:12164941, PMID:24003391 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptk7 protein tyrosine kinase 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTK7 mRNA CTD PMID:20823114 NCBI chr 9:16,662,588...16,729,888
Ensembl chr 9:16,702,460...16,729,030
JBrowse link
G Ptpa protein phosphatase 2 phosphatase activator multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of PTPA mRNA CTD PMID:20823114 NCBI chr 3:8,982,122...9,012,585
Ensembl chr 3:8,982,122...9,012,585
JBrowse link
G Rab1b RAB1B, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB1B mRNA CTD PMID:20823114 NCBI chr 1:220,483,529...220,491,469
Ensembl chr 1:220,480,834...220,491,469
JBrowse link
G Rab31 RAB31, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RAB31 mRNA CTD PMID:20823114 NCBI chr 9:113,370,072...113,504,606
Ensembl chr 9:113,370,033...113,504,605
JBrowse link
G Ran RAN, member RAS oncogene family multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RAN mRNA CTD PMID:20823114 NCBI chr12:31,319,556...31,324,105
Ensembl chr12:31,320,624...31,323,810
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases activity
decreases phosphorylation
multiple interactions
ISO
EXP
Bucladesine results in decreased activity of RB1 protein
Bucladesine results in decreased phosphorylation of RB1 protein
Bucladesine inhibits the reaction [CASP3 protein results in increased cleavage of RB1 protein]
CTD PMID:10697531, PMID:16718685 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Ren renin increases secretion
increases expression
ISO Bucladesine results in increased secretion of REN protein
Bucladesine results in increased expression of REN mRNA
CTD PMID:9256163 NCBI chr13:50,502,724...50,513,953
Ensembl chr13:50,502,724...50,514,151
JBrowse link
G Ret ret proto-oncogene multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RET mRNA CTD PMID:20823114 NCBI chr 4:150,202,170...150,249,196
Ensembl chr 4:150,202,058...150,244,372
JBrowse link
G Rgs10 regulator of G-protein signaling 10 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RGS10 mRNA CTD PMID:20823114 NCBI chr 1:199,782,076...199,823,440
Ensembl chr 1:199,782,078...199,823,386
JBrowse link
G Rhobtb3 Rho-related BTB domain containing 3 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RHOBTB3 mRNA CTD PMID:20823114 NCBI chr 2:2,627,655...2,683,305
Ensembl chr 2:2,627,393...2,683,116
JBrowse link
G Rin1 Ras and Rab interactor 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RIN1 mRNA CTD PMID:20823114 NCBI chr 1:220,335,036...220,342,319
Ensembl chr 1:220,335,254...220,342,297
JBrowse link
G Rpn1 ribophorin I multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPN1 mRNA CTD PMID:20823114 NCBI chr 4:119,997,232...120,018,687
Ensembl chr 4:119,997,268...120,018,679
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of RPS6KB1 mRNA CTD PMID:20823114 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rpsa ribosomal protein SA multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of RPSA mRNA CTD PMID:20823114 NCBI chr 8:128,806,053...128,809,987
Ensembl chr 8:128,806,129...128,809,986
JBrowse link
G S100a14 S100 calcium binding protein A14 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of S100A14 mRNA CTD PMID:20823114 NCBI chr 2:189,913,433...189,919,947 JBrowse link
G Saraf store-operated calcium entry-associated regulatory factor multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SARAF mRNA CTD PMID:20823114 NCBI chr16:61,735,189...61,753,438
Ensembl chr16:61,735,181...61,753,476
JBrowse link
G Scamp4 secretory carrier membrane protein 4 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SCAMP4 mRNA CTD PMID:20823114 NCBI chr 7:11,969,720...11,982,141
Ensembl chr 7:11,969,720...11,982,141
JBrowse link
G Scarb1 scavenger receptor class B, member 1 multiple interactions
increases expression
ISO
EXP
LIPE protein affects the reaction [Bucladesine results in increased expression of SCARB1 mRNA] CTD PMID:23045399, PMID:23362264 NCBI chr12:36,694,952...36,761,445
Ensembl chr12:36,694,960...36,761,455
JBrowse link
G Sdcbp syndecan binding protein multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SDCBP mRNA CTD PMID:20823114 NCBI chr 5:19,471,664...19,498,499
Ensembl chr 5:19,471,664...19,498,485
JBrowse link
G Selenot selenoprotein T multiple interactions
increases expression
EXP 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA]; nickel chloride inhibits the reaction [Bucladesine results in increased expression of SELENOT mRNA] CTD PMID:18198219 NCBI chr 2:148,765,412...148,781,080
Ensembl chr 2:148,765,412...148,780,276
JBrowse link
G Sema3a semaphorin 3A multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of SEMA3A mRNA CTD PMID:20823114 NCBI chr 4:18,170,375...18,545,190
Ensembl chr 4:18,178,656...18,396,035
JBrowse link
G Septin11 septin 11 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SEPTIN11 mRNA CTD PMID:20823114 NCBI chr14:16,369,544...16,405,645
Ensembl chr14:16,369,544...16,452,998
JBrowse link
G Sfn stratifin multiple interactions ISO [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine co-treated with decitabine] results in increased expression of SFN mRNA; [Estradiol co-treated with Medroxyprogesterone Acetate co-treated with Bucladesine] results in increased expression of SFN protein CTD PMID:22534328 NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
JBrowse link
G Slc18a3 solute carrier family 18 member A3 increases expression
multiple interactions
EXP Bucladesine results in increased expression of SLC18A3 protein
Nicotine promotes the reaction [Bucladesine results in increased expression of SLC18A3 protein]
CTD PMID:20361958 NCBI chr16:8,682,668...8,685,529
Ensembl chr16:8,682,669...8,685,529
JBrowse link
G Slc2a1 solute carrier family 2 member 1 multiple interactions ISO [Progesterone co-treated with Bucladesine] results in increased expression of SLC2A1 protein CTD PMID:18948400 NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
JBrowse link
G Slc2a5 solute carrier family 2 member 5 multiple interactions ISO Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased stability of SLC2A5 mRNA] CTD PMID:12820898 NCBI chr 5:167,142,182...167,174,203
Ensembl chr 5:167,141,875...167,174,310
JBrowse link
G Smad6 SMAD family member 6 multiple interactions ISO Bucladesine inhibits the reaction [BMP4 protein results in increased expression of SMAD6 mRNA] CTD PMID:20522807 NCBI chr 8:68,897,746...68,967,221
Ensembl chr 8:68,898,296...68,966,108
JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression
increases activity
ISO Bucladesine promotes the reaction [CREBBP protein binds to SOD2 promoter]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of SOD2 mRNA]; protein kinase inhibitor peptide inhibits the reaction [Bucladesine results in increased activity of SOD2 protein] CTD PMID:12093828, PMID:20685861 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
JBrowse link
G Sox1 SRY-box transcription factor 1 multiple interactions
affects expression
ISO bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; bisphenol A affects the reaction [Bucladesine affects the expression of SOX1 protein]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Methylmercury Compounds affects the reaction [Bucladesine affects the expression of SOX1 protein]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 mRNA]; Paraquat affects the reaction [Bucladesine affects the expression of SOX1 protein]
Bucladesine affects the expression of SOX1 mRNA; Bucladesine affects the expression of SOX1 protein
CTD PMID:31400064
G Srsf7 serine and arginine rich splicing factor 7 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SRSF7 mRNA CTD PMID:20823114 NCBI chr 6:2,879,312...2,886,505
Ensembl chr 6:2,880,518...2,886,465
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions
increases expression
decreases expression
ISO
EXP
27-hydroxycholesterol promotes the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; [[TO-901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]] which results in increased abundance of Progesterone; [Bucladesine co-treated with ciglitazone] results in increased expression of STAR mRNA; [Bucladesine co-treated with ciglitazone] results in increased phosphorylation of STAR protein; [Bucladesine co-treated with LIPE protein] results in increased expression of and results in increased phosphorylation of STAR protein; [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]] promotes the reaction [CREBBP protein binds to STAR promoter]; [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone; [Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone; [ciglitazone co-treated with Bucladesine] promotes the reaction [JUN protein results in increased expression of STAR mRNA]; [TO-901317 co-treated with LG 100268] promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; alpha-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; bisindolylmaleimide I inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; bisindolylmaleimide I inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR mRNA]; Bucladesine promotes the reaction [ciglitazone results in increased expression of STAR protein]; Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[TO-901317 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [[TO-901317 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [LG 100268 promotes the reaction [TO-901317 results in increased expression of STAR mRNA]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [[LG 100268 results in increased expression of STAR mRNA] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [[LG 100268 results in increased expression of STAR protein] which results in increased abundance of Progesterone]]; Bucladesine promotes the reaction [TO-901317 promotes the reaction [LG 100268 results in increased expression of STAR mRNA]]; Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA; Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein; CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; ciglitazone promotes the reaction [Bucladesine results in increased expression of STAR protein]; CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; CREBBP protein promotes the reaction [CREB1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; delta-hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; GFX 109203x inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Hexachlorocyclohexane inhibits the reaction [Bucladesine results in increased expression of STAR protein]; lead acetate inhibits the reaction [Bucladesine results in increased expression of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; LIPE protein affects the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR0B1 protein inhibits the reaction [[Bucladesine results in increased expression of STAR protein] which results in increased abundance of Progesterone]; NR0B1 protein inhibits the reaction [NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR0B1 protein inhibits the reaction [NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR1H2 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR1H3 protein affects the reaction [CAY 10499 inhibits the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]]; NR4A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; NR4A1 protein promotes the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]]; NR5A1 protein promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Probucol inhibits the reaction [STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased expression of ABCA1 mRNA]; STAR protein promotes the reaction [[Bucladesine co-treated with APOA1 protein] results in increased secretion of Cholesterol]; Tetradecanoylphorbol Acetate promotes the reaction [[Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein] which results in increased abundance of Progesterone]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine promotes the reaction [CREB1 protein modified form binds to STAR promoter]]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of and results in increased phosphorylation of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased expression of STAR protein]; Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Bucladesine results in increased phosphorylation of STAR protein]; U 0126 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Bucladesine results in increased phosphorylation of STAR protein]]
Bucladesine results in increased expression of STAR mRNA; Bucladesine results in increased expression of STAR protein
Bucladesine results in decreased expression of STAR mRNA
[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA; Atrazine inhibits the reaction [Bucladesine results in increased expression of STAR mRNA]; Quercetin inhibits the reaction [[Atrazine co-treated with Bucladesine] results in increased expression of STAR mRNA]
CTD PMID:10964798, PMID:10993823, PMID:11213355, PMID:18755854, PMID:18787026, PMID:19253104, PMID:19282384, PMID:19698295, PMID:20083572, PMID:21047949, PMID:21693180, PMID:21979172, PMID:23200735, PMID:23362264 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO STAT3 gene mutant form affects the reaction [IL22 protein inhibits the reaction [Bucladesine results in increased expression of G6PC protein]] CTD PMID:26064446 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stk38 serine/threonine kinase 38 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of STK38 mRNA CTD PMID:20823114 NCBI chr20:6,224,300...6,257,613
Ensembl chr20:6,224,296...6,257,604
JBrowse link
G Sulf1 sulfatase 1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of SULF1 mRNA CTD PMID:20823114 NCBI chr 5:5,999,520...6,186,901
Ensembl chr 5:5,999,475...6,186,329
JBrowse link
G Tagln transgelin multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TAGLN mRNA CTD PMID:20823114 NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
JBrowse link
G Tcea1 transcription elongation factor A1 multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in decreased expression of TCEA1 mRNA CTD PMID:20823114 NCBI chr 5:14,511,183...14,548,494
Ensembl chr 5:14,511,183...14,548,429
JBrowse link
G Tert telomerase reverse transcriptase multiple interactions ISO [Estradiol co-treated with Bucladesine co-treated with Medroxyprogesterone Acetate] results in increased expression of TERT mRNA CTD PMID:20823114 NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
JBrowse link
G Testin testin gene decreases expression
multiple interactions
EXP Bucladesine results in decreased expression of TESTIN mRNA
Dactinomycin inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]; lonidamine inhibits the reaction [Bucladesine results in decreased expression of TESTIN mRNA]
CTD PMID:11090432 NCBI chr17:4,194,796...4,225,376
Ensembl chr17:4,212,890...4,225,376
JBrowse link
G Tfrc transferrin receptor decreases expression ISO Bucladesine results in decreased expression of TFRC protein CTD PMID:2989362 NCBI chr11:71,397,423...71,419,263
Ensembl chr11:71,397,383...71,419,223
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA]; Bucladesine inhibits the reaction [TGFB1 protein results in increased expression of COL3A1 mRNA] CTD